



## Clinical trial results:

### **A Phase 3 Randomized, Double Blind Study Assessing the Efficacy and Safety of PF-06410293 and Adalimumab in Combination With Methotrexate in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate**

#### **Summary**

EudraCT number	2014-000352-29
Trial protocol	CZ EE LT HU GB DE ES FR BG HR
Global end of trial date	06 December 2017

#### **Results information**

Result version number	v2
This version publication date	22 December 2018
First version publication date	13 September 2017
Version creation reason	

#### **Trial information**

##### **Trial identification**

Sponsor protocol code	B5381002
-----------------------	----------

##### **Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02480153
WHO universal trial number (UTN)	-

Notes:

##### **Sponsors**

Sponsor organisation name	Pfizer, Inc.
Sponsor organisation address	235 E 42nd Street, New York, United States, NY 10017
Public contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., +1 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com
Scientific contact	Pfizer ClinicalTrials.gov Call Center, Pfizer, Inc., +1 18007181021, ClinicalTrials.gov_Inquiries@pfizer.com

Notes:

##### **Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 July 2018
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	06 December 2017
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study was to compare the treatment efficacy between adalimumab-Pfizer (PF-06410293) and adalimumab-EU (adalimumab sourced from the European Union) in subjects with moderately to severely active rheumatoid arthritis who were treated with adalimumab in combination with methotrexate.

Protection of trial subjects:

This study was conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Council for Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. In addition, all local regulatory requirements were followed, in particular, those affording greater protection to the safety of trial subjects.

Background therapy:

Subjects continued their stable background regimen of oral or intramuscular methotrexate (10 to 25 mg/week, with the exception of 6 to 25 mg/week in geographic regions where 6 mg/week was a recommended initial dose by local guidance or standard of care) throughout the study.

Evidence for comparator:

This study was designed to compare the treatment efficacy between PF-06410293 and adalimumab-EU; therefore, adalimumab-EU was used as the comparator.

Actual start date of recruitment	25 June 2015
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	4 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 5
Country: Number of subjects enrolled	Brazil: 2
Country: Number of subjects enrolled	Bulgaria: 37
Country: Number of subjects enrolled	Colombia: 3
Country: Number of subjects enrolled	Czech Republic: 31
Country: Number of subjects enrolled	Estonia: 3
Country: Number of subjects enrolled	Georgia: 33
Country: Number of subjects enrolled	Germany: 13
Country: Number of subjects enrolled	Hungary: 14
Country: Number of subjects enrolled	Japan: 17
Country: Number of subjects enrolled	Korea, Republic of: 6
Country: Number of subjects enrolled	Lithuania: 30

Country: Number of subjects enrolled	Mexico: 10
Country: Number of subjects enrolled	New Zealand: 4
Country: Number of subjects enrolled	Peru: 24
Country: Number of subjects enrolled	Poland: 87
Country: Number of subjects enrolled	Russian Federation: 56
Country: Number of subjects enrolled	Serbia: 35
Country: Number of subjects enrolled	South Africa: 15
Country: Number of subjects enrolled	Spain: 21
Country: Number of subjects enrolled	Taiwan: 5
Country: Number of subjects enrolled	Ukraine: 66
Country: Number of subjects enrolled	United Kingdom: 5
Country: Number of subjects enrolled	United States: 75
Worldwide total number of subjects	597
EEA total number of subjects	241

Notes:

### **Subjects enrolled per age group**

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	480
From 65 to 84 years	117
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

A total of 1231 potential subjects were screened after signing an informed consent form, of whom 597 subjects were randomized to receive study treatment.

### Period 1

Period 1 title	Period 1: First Dose to Week 26 Pre-dose
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	PF-06410293

Arm description:

Subjects in this reporting group were initially randomized to the PF-06410293 group in Period 1, and received PF-06410293 (a potential biosimilar to Humira) 40 mg every 2 weeks by subcutaneous injection in all the 3 treatment periods. Period 1 began with the first dose of blinded study drug and ended with the completion of Week 26 pre-dose assessments. Period 2 began with the blinded study drug dosing at Week 26 and ended with the completion of Week 52 pre-dose assessments. Period 3 began with open-label PF-06410293 dosing at Week 52 and ended with end of treatment visit at Week 78. Subjects were followed up for 16 weeks after the last dose of study drug (up to Week 92).

Arm type	Experimental
Investigational medicinal product name	PF-06410293
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

PF-06410293 40 mg was administered every other week by subcutaneous injection in Period 1.

<b>Arm title</b>	Adalimumab-EU
------------------	---------------

Arm description:

Subjects in this reporting group were initially randomized to the adalimumab-EU group in Period 1, and received adalimumab-EU (Humira from European Union) 40 mg every 2 weeks by subcutaneous injection in Period 1 which began with the first dose of study drug and ended with the completion of Week 26 pre-dose assessments. A second randomization was blindly performed prior to dosing at Week 26, when subjects initially randomized to adalimumab-EU were re-randomized in a 1:1 ratio, with 50% of the subjects switching to PF-06410293 and the other 50% remaining in the adalimumab-EU arm. Period 2 began with the study drug dosing at Week 26 and ended with the completion of Week 52 pre-dose assessments. Period 3 began with open-label PF-06410293 dosing at Week 52 and ended with end of treatment visit at Week 78. Subjects were followed up for 16 weeks after the last dose of study drug (up to Week 92).

Arm type	Experimental
Investigational medicinal product name	Adalimumab-EU
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Adalimumab-EU 40 mg was administered every other week by subcutaneous injection in Period 1.

<b>Number of subjects in period 1</b>	PF-06410293	Adalimumab-EU
Started	297	300
Received treatment	297	299
Completed	293	284
Not completed	4	16
Adverse event, serious fatal	-	1
Consent withdrawn by subject	3	8
Adverse event, non-fatal	1	2
Non-compliance with study treatment	-	1
Unspecified	-	1
Lost to follow-up	-	2
Insufficient clinical response	-	1

## Period 2

Period 2 title	Period 2: Week 26 to Week 52 Pre-dose
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Carer

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	PF-06410293

### Arm description:

Subjects in this reporting group were initially randomized to the PF-06410293 group in Period 1, and received PF-06410293 (a potential biosimilar to Humira) 40 mg every 2 weeks by subcutaneous injection in all the 3 treatment periods. Period 1 began with the first dose of blinded study drug and ended with the completion of Week 26 pre-dose assessments. Period 2 began with the blinded study drug dosing at Week 26 and ended with the completion of Week 52 pre-dose assessments. Period 3 began with open-label PF-06410293 dosing at Week 52 and ended with end of treatment visit at Week 78. Subjects were followed up for 16 weeks after the last dose of study drug (up to Week 92).

Arm type	Experimental
Investigational medicinal product name	PF-06410293
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

### Dosage and administration details:

PF-06410293 40 mg was administered every other week by subcutaneous injection in Period 2.

<b>Arm title</b>	Adalimumab-EU
------------------	---------------

**Arm description:**

Subjects in this reporting group were initially randomized to the adalimumab-EU group in Period 1, and received adalimumab-EU (Humira from European Union) 40 mg every 2 weeks by subcutaneous injection in Period 1 which began with the first dose of study drug and ended with the completion of Week 26 pre-dose assessments. A second randomization was blindly performed prior to dosing at Week 26, when subjects initially randomized to adalimumab-EU were re-randomized in a 1:1 ratio, with 50% of the subjects switching to PF-06410293 and the other 50% remaining in the adalimumab-EU arm. Period 2 began with the study drug dosing at Week 26 and ended with the completion of Week 52 pre-dose assessments. Period 3 began with open-label PF-06410293 dosing at Week 52 and ended with end of treatment visit at Week 78. Subjects were followed up for 16 weeks after the last dose of study drug (up to Week 92).

Arm type	Experimental
Investigational medicinal product name	Adalimumab-EU and PF-06410293
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

**Dosage and administration details:**

Re-randomization was performed at the beginning of Period 2, with 50% of subjects switching to PF-06410293 and the other 50% of subjects remaining on adalimumab-EU. Study drug 40 mg was administered every other week by subcutaneous injection.

<b>Number of subjects in period 2<sup>[1]</sup></b>	PF-06410293	Adalimumab-EU
Started	283	269
Received treatment	283	268
Completed	263	249
Not completed	20	20
Consent withdrawn by subject	8	4
Adverse event, non-fatal	6	10
Non-compliance with study treatment	-	1
Unspecified	2	-
Lost to follow-up	-	1
Insufficient clinical response	4	4

**Notes:**

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Some subjects completed the preceding period, but discontinued before entering this period

**Period 3**

Period 3 title	Period 3: Week 52 dosing to Week 78
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

**Arms**

Are arms mutually exclusive?	Yes
------------------------------	-----

<b>Arm title</b>	PF-06410293
Arm description:	
Subjects in this reporting group were initially randomized to the PF-06410293 group in Period 1, and received PF-06410293 (a potential biosimilar to Humira) 40 mg every 2 weeks by subcutaneous injection in all the 3 treatment periods. Period 1 began with the first dose of blinded study drug and ended with the completion of Week 26 pre-dose assessments. Period 2 began with the blinded study drug dosing at Week 26 and ended with the completion of Week 52 pre-dose assessments. Period 3 began with open-label PF-06410293 dosing at Week 52 and ended with end of treatment visit at Week 78. Subjects were followed up for 16 weeks after the last dose of study drug (up to Week 92).	
Arm type	Experimental
Investigational medicinal product name	PF-06410293
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
PF-06410293 40 mg was administered every other week by subcutaneous injection in Period 3.	
<b>Arm title</b>	Adalimumab-EU

Arm description:	
Subjects in this reporting group were initially randomized to the adalimumab-EU group in Period 1, and received adalimumab-EU (Humira from European Union) 40 mg every 2 weeks by subcutaneous injection in Period 1 which began with the first dose of study drug and ended with the completion of Week 26 pre-dose assessments. A second randomization was blindly performed prior to dosing at Week 26, when subjects initially randomized to adalimumab-EU were re-randomized in a 1:1 ratio, with 50% of the subjects switching to PF-06410293 and the other 50% remaining in the adalimumab-EU arm. Period 2 began with the study drug dosing at Week 26 and ended with the completion of Week 52 pre-dose assessments. Period 3 began with open-label PF-06410293 dosing at Week 52 and ended with end of treatment visit at Week 78. Subjects were followed up for 16 weeks after the last dose of study drug (up to Week 92).	
Arm type	Experimental
Investigational medicinal product name	PF-06410293
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
PF-06410293 40 mg was administered every other week by subcutaneous injection in Period 3.	

<b>Number of subjects in period 3<sup>[2]</sup></b>	PF-06410293	Adalimumab-EU
Started	259	248
Received treatment	258	247
Completed	252	241
Not completed	7	7
Adverse event, serious fatal	-	1
Consent withdrawn by subject	3	3
Adverse event, non-fatal	-	1
Unspecified	-	1
Lost to follow-up	4	1

---

Notes:

[2] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Some subjects completed the preceding period, but discontinued before entering this period

## Baseline characteristics

### Reporting groups

Reporting group title	PF-06410293
-----------------------	-------------

Reporting group description:

Subjects in this reporting group were initially randomized to the PF-06410293 group in Period 1, and received PF-06410293 (a potential biosimilar to Humira) 40 mg every 2 weeks by subcutaneous injection in all the 3 treatment periods. Period 1 began with the first dose of blinded study drug and ended with the completion of Week 26 pre-dose assessments. Period 2 began with the blinded study drug dosing at Week 26 and ended with the completion of Week 52 pre-dose assessments. Period 3 began with open-label PF-06410293 dosing at Week 52 and ended with end of treatment visit at Week 78. Subjects were followed up for 16 weeks after the last dose of study drug (up to Week 92).

Reporting group title	Adalimumab-EU
-----------------------	---------------

Reporting group description:

Subjects in this reporting group were initially randomized to the adalimumab-EU group in Period 1, and received adalimumab-EU (Humira from European Union) 40 mg every 2 weeks by subcutaneous injection in Period 1 which began with the first dose of study drug and ended with the completion of Week 26 pre-dose assessments. A second randomization was blindly performed prior to dosing at Week 26, when subjects initially randomized to adalimumab-EU were re-randomized in a 1:1 ratio, with 50% of the subjects switching to PF-06410293 and the other 50% remaining in the adalimumab-EU arm. Period 2 began with the study drug dosing at Week 26 and ended with the completion of Week 52 pre-dose assessments. Period 3 began with open-label PF-06410293 dosing at Week 52 and ended with end of treatment visit at Week 78. Subjects were followed up for 16 weeks after the last dose of study drug (up to Week 92).

Reporting group values	PF-06410293	Adalimumab-EU	Total
Number of subjects	297	300	597
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	245	235	480
From 65-84 years	52	65	117
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	51.5	53.5	-
standard deviation	± 13.6	± 12.9	-
Sex: Female, Male Units: Subjects			
Female	241	229	470
Male	56	71	127
Race/Ethnicity, Customized Units: Subjects			
White	261	256	517
Black	6	9	15
Asian	16	17	33
Other	14	18	32

---

## Subject analysis sets

Subject analysis set title	Period 1: PF-06410293
Subject analysis set type	Intention-to-treat

Subject analysis set description:

This reporting group refers to the subjects who were randomized to the PF-06410293 group in Period 1, where PF-06410293 40 mg was administered every other week by subcutaneous injection.

Subject analysis set title	Period 1: Adalimumab-EU
Subject analysis set type	Intention-to-treat

Subject analysis set description:

This reporting group refers to the subjects who were randomized to the adalimumab-EU group in Period 1, where adalimumab-EU 40 mg was administered every other week by subcutaneous injection.

Subject analysis set title	Period 2: PF-06410293/PF-06410293
Subject analysis set type	Intention-to-treat

Subject analysis set description:

This reporting group refers to the subjects who were randomized to the PF-06410293 group in Period 1 and continued to receive PF-06410293 in Period 2. PF-06410293 40 mg was administered every other week by subcutaneous injection in both periods.

Subject analysis set title	Period 2: Adalimumab-EU/Adalimumab-EU
Subject analysis set type	Intention-to-treat

Subject analysis set description:

This reporting group refers to the subjects who were randomized to the adalimumab-EU group in Period 1 and remained in the adalimumab-EU group in Period 2. Adalimumab-EU 40 mg was administered every other week by subcutaneous injection in both periods.

Subject analysis set title	Period 2: Adalimumab-EU/PF-06410293
Subject analysis set type	Intention-to-treat

Subject analysis set description:

This reporting group refers to the subjects who were randomized to the adalimumab-EU group in Period 1 and switched to PF-06410293 in Period 2. Study drug 40 mg was administered every other week by subcutaneous injection in both periods.

Subject analysis set title	Period 3: PF-06410293/PF-06410293/PF-06410293
Subject analysis set type	Intention-to-treat

Subject analysis set description:

This reporting group refers to the subjects who were randomized to the PF-06410293 group in Period 1 and continued to receive PF-06410293 in Period 2 and Period 3. PF-06410293 40 mg was administered every other week by subcutaneous injection in all 3 periods.

Subject analysis set title	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293
Subject analysis set type	Intention-to-treat

Subject analysis set description:

This reporting group refers to the subjects who were randomized to the adalimumab-EU group in Period 1, remained in the adalimumab-EU group in Period 2 and received PF-06410293 in Period 3. Study drug 40 mg was administered every other week by subcutaneous injection in all 3 periods.

Subject analysis set title	Period 3: Adalimumab-EU/PF-06410293/PF-06410293
Subject analysis set type	Intention-to-treat

Subject analysis set description:

This reporting group refers to the subjects who were randomized to the adalimumab-EU group in Period 1 and switched to PF-06410293 from Period 2 and continued on PF-06410293 in Period 3. Study drug 40 mg was administered every other week by subcutaneous injection in all 3 periods.

Subject analysis set title	Period 3 Total
Subject analysis set type	Intention-to-treat

Subject analysis set description:

This reporting group refers to the subjects who entered Period 3, where PF-06410293 40 mg was

administered every other week by subcutaneous injection.

Subject analysis set title	Sub-study: PF-06410293 PFP
Subject analysis set type	Intention-to-treat

Subject analysis set description:

Subjects received 6 consecutive bi-weekly PF-06410293 doses over a period of 10 weeks (Week 56 to Week 66) using the PFP device provided by the sponsor. The first, third and sixth injections were administered at the study site under the supervision of the investigator or a designated observer. All other injections (the second, fourth and fifth) were administered at home.

Reporting group values	Period 1: PF-06410293	Period 1: Adalimumab-EU	Period 2: PF-06410293/PF-06410293
Number of subjects	297	300	283
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	245	235	234
From 65-84 years	52	65	49
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	51.5	53.5	51.3
standard deviation	± 13.6	± 12.9	± 13.7
Sex: Female, Male Units: Subjects			
Female	241	229	229
Male	56	71	54
Race/Ethnicity, Customized Units: Subjects			
White	261	256	250
Black	6	9	6
Asian	16	17	14
Other	14	18	13

Reporting group values	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	Period 3: PF-06410293/PF-06410293/PF-06410293
Number of subjects	135	134	259
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0

Adults (18-64 years)	106	103	215
From 65-84 years	29	31	44
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	53.6	53.4	51.1
standard deviation	± 12.1	± 13.4	± 13.8
Sex: Female, Male			
Units: Subjects			
Female	108	95	210
Male	27	39	49
Race/Ethnicity, Customized			
Units: Subjects			
White	113	116	230
Black	7	2	5
Asian	8	6	11
Other	7	10	13

<b>Reporting group values</b>	Period 3: Adalimumab- EU/Adalimumab- EU/PF-06410293	Period 3: Adalimumab-EU/PF- 06410293/PF- 06410293	Period 3 Total
Number of subjects	121	127	507
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	99	98	412
From 65-84 years	22	29	95
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	53.1	53.1	52.1
standard deviation	± 11.7	± 13.5	± 13.3
Sex: Female, Male			
Units: Subjects			
Female	98	88	396
Male	23	39	111
Race/Ethnicity, Customized			
Units: Subjects			
White	100	109	439
Black	7	2	14
Asian	7	6	24
Other	7	10	30

<b>Reporting group values</b>	Sub-study: PF- 06410293 PFP		
Number of subjects	50		

Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	36		
From 65-84 years	14		
85 years and over	0		
Age Continuous			
Units: years			
arithmetic mean	54.9		
standard deviation	± 13.1		
Sex: Female, Male			
Units: Subjects			
Female	37		
Male	13		
Race/Ethnicity, Customized			
Units: Subjects			
White	46		
Black	4		
Asian	0		
Other	0		

## End points

### End points reporting groups

Reporting group title	PF-06410293
-----------------------	-------------

Reporting group description:

Subjects in this reporting group were initially randomized to the PF-06410293 group in Period 1, and received PF-06410293 (a potential biosimilar to Humira) 40 mg every 2 weeks by subcutaneous injection in all the 3 treatment periods. Period 1 began with the first dose of blinded study drug and ended with the completion of Week 26 pre-dose assessments. Period 2 began with the blinded study drug dosing at Week 26 and ended with the completion of Week 52 pre-dose assessments. Period 3 began with open-label PF-06410293 dosing at Week 52 and ended with end of treatment visit at Week 78. Subjects were followed up for 16 weeks after the last dose of study drug (up to Week 92).

Reporting group title	Adalimumab-EU
-----------------------	---------------

Reporting group description:

Subjects in this reporting group were initially randomized to the adalimumab-EU group in Period 1, and received adalimumab-EU (Humira from European Union) 40 mg every 2 weeks by subcutaneous injection in Period 1 which began with the first dose of study drug and ended with the completion of Week 26 pre-dose assessments. A second randomization was blindly performed prior to dosing at Week 26, when subjects initially randomized to adalimumab-EU were re-randomized in a 1:1 ratio, with 50% of the subjects switching to PF-06410293 and the other 50% remaining in the adalimumab-EU arm. Period 2 began with the study drug dosing at Week 26 and ended with the completion of Week 52 pre-dose assessments. Period 3 began with open-label PF-06410293 dosing at Week 52 and ended with end of treatment visit at Week 78. Subjects were followed up for 16 weeks after the last dose of study drug (up to Week 92).

Reporting group title	PF-06410293
-----------------------	-------------

Reporting group description:

Subjects in this reporting group were initially randomized to the PF-06410293 group in Period 1, and received PF-06410293 (a potential biosimilar to Humira) 40 mg every 2 weeks by subcutaneous injection in all the 3 treatment periods. Period 1 began with the first dose of blinded study drug and ended with the completion of Week 26 pre-dose assessments. Period 2 began with the blinded study drug dosing at Week 26 and ended with the completion of Week 52 pre-dose assessments. Period 3 began with open-label PF-06410293 dosing at Week 52 and ended with end of treatment visit at Week 78. Subjects were followed up for 16 weeks after the last dose of study drug (up to Week 92).

Reporting group title	Adalimumab-EU
-----------------------	---------------

Reporting group description:

Subjects in this reporting group were initially randomized to the adalimumab-EU group in Period 1, and received adalimumab-EU (Humira from European Union) 40 mg every 2 weeks by subcutaneous injection in Period 1 which began with the first dose of study drug and ended with the completion of Week 26 pre-dose assessments. A second randomization was blindly performed prior to dosing at Week 26, when subjects initially randomized to adalimumab-EU were re-randomized in a 1:1 ratio, with 50% of the subjects switching to PF-06410293 and the other 50% remaining in the adalimumab-EU arm. Period 2 began with the study drug dosing at Week 26 and ended with the completion of Week 52 pre-dose assessments. Period 3 began with open-label PF-06410293 dosing at Week 52 and ended with end of treatment visit at Week 78. Subjects were followed up for 16 weeks after the last dose of study drug (up to Week 92).

Reporting group title	PF-06410293
-----------------------	-------------

Reporting group description:

Subjects in this reporting group were initially randomized to the PF-06410293 group in Period 1, and received PF-06410293 (a potential biosimilar to Humira) 40 mg every 2 weeks by subcutaneous injection in all the 3 treatment periods. Period 1 began with the first dose of blinded study drug and ended with the completion of Week 26 pre-dose assessments. Period 2 began with the blinded study drug dosing at Week 26 and ended with the completion of Week 52 pre-dose assessments. Period 3 began with open-label PF-06410293 dosing at Week 52 and ended with end of treatment visit at Week 78. Subjects were followed up for 16 weeks after the last dose of study drug (up to Week 92).

Reporting group title	Adalimumab-EU
-----------------------	---------------

Reporting group description:

Subjects in this reporting group were initially randomized to the adalimumab-EU group in Period 1, and received adalimumab-EU (Humira from European Union) 40 mg every 2 weeks by subcutaneous injection in Period 1 which began with the first dose of study drug and ended with the completion of Week 26 pre-dose assessments. A second randomization was blindly performed prior to dosing at Week 26, when subjects initially randomized to adalimumab-EU were re-randomized in a 1:1 ratio, with 50% of the subjects switching to PF-06410293 and the other 50% remaining in the adalimumab-EU arm.

Period 2 began with the study drug dosing at Week 26 and ended with the completion of Week 52 pre-dose assessments. Period 3 began with open-label PF-06410293 dosing at Week 52 and ended with end of treatment visit at Week 78. Subjects were followed up for 16 weeks after the last dose of study drug (up to Week 92).

Subject analysis set title	Period 1: PF-06410293
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
This reporting group refers to the subjects who were randomized to the PF-06410293 group in Period 1, where PF-06410293 40 mg was administered every other week by subcutaneous injection.	
Subject analysis set title	Period 1: Adalimumab-EU
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
This reporting group refers to the subjects who were randomized to the adalimumab-EU group in Period 1, where adalimumab-EU 40 mg was administered every other week by subcutaneous injection.	
Subject analysis set title	Period 2: PF-06410293/PF-06410293
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
This reporting group refers to the subjects who were randomized to the PF-06410293 group in Period 1 and continued to receive PF-06410293 in Period 2. PF-06410293 40 mg was administered every other week by subcutaneous injection in both periods.	
Subject analysis set title	Period 2: Adalimumab-EU/Adalimumab-EU
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
This reporting group refers to the subjects who were randomized to the adalimumab-EU group in Period 1 and remained in the adalimumab-EU group in Period 2. Adalimumab-EU 40 mg was administered every other week by subcutaneous injection in both periods.	
Subject analysis set title	Period 2: Adalimumab-EU/PF-06410293
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
This reporting group refers to the subjects who were randomized to the adalimumab-EU group in Period 1 and switched to PF-06410293 in Period 2. Study drug 40 mg was administered every other week by subcutaneous injection in both periods.	
Subject analysis set title	Period 3: PF-06410293/PF-06410293/PF-06410293
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
This reporting group refers to the subjects who were randomized to the PF-06410293 group in Period 1 and continued to receive PF-06410293 in Period 2 and Period 3. PF-06410293 40 mg was administered every other week by subcutaneous injection in all 3 periods.	
Subject analysis set title	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
This reporting group refers to the subjects who were randomized to the adalimumab-EU group in Period 1, remained in the adalimumab-EU group in Period 2 and received PF-06410293 in Period 3. Study drug 40 mg was administered every other week by subcutaneous injection in all 3 periods.	
Subject analysis set title	Period 3: Adalimumab-EU/PF-06410293/PF-06410293
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
This reporting group refers to the subjects who were randomized to the adalimumab-EU group in Period 1 and switched to PF-06410293 from Period 2 and continued on PF-06410293 in Period 3. Study drug 40 mg was administered every other week by subcutaneous injection in all 3 periods.	
Subject analysis set title	Period 3 Total
Subject analysis set type	Intention-to-treat
Subject analysis set description:	
This reporting group refers to the subjects who entered Period 3, where PF-06410293 40 mg was administered every other week by subcutaneous injection.	
Subject analysis set title	Sub-study: PF-06410293 PFP
Subject analysis set type	Intention-to-treat

Subject analysis set description:

Subjects received 6 consecutive bi-weekly PF-06410293 doses over a period of 10 weeks (Week 56 to Week 66) using the PFP device provided by the sponsor. The first, third and sixth injections were administered at the study site under the supervision of the investigator or a designated observer. All other injections (the second, fourth and fifth) were administered at home.

**Primary: Percentage of Subjects with an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1**

End point title	Percentage of Subjects with an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1
-----------------	---

End point description:

ACR20 is a categorical variable indicating a 20% or greater improvement in tender and swollen joint counts and 20% or greater improvement in 3 of the 5 other ACR-core set measures: patient's assessment of arthritis pain (PAAP); patient's global assessment of arthritis (PGA); physician's global assessment of arthritis (PGAA); high sensitivity C-reactive protein (hs-CRP); and Health Assessment Questionnaire - Disability Index (HAQ-DI). The analysis population included all subjects who were randomized to study treatment.

End point type	Primary
----------------	---------

End point timeframe:

Week 12

End point values	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	300		
Units: percentage of subjects				
number (not applicable)	68.35	71.33		

**Statistical analyses**

<b>Statistical analysis title</b>	Percentage difference with 95% CI
Comparison groups	Period 1: PF-06410293 v Period 1: Adalimumab-EU
Number of subjects included in analysis	597
Analysis specification	Pre-specified
Analysis type	equivalence <sup>[1]</sup>
Parameter estimate	Week 12 ACR20 response rate difference
Point estimate	-2.98
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.38
upper limit	4.44

Notes:

[1] - Confidence interval (CIs) calculated by the score statistic method were used for the inference of the equivalence for ACR20 at Week 12. Therapeutic equivalence could be established if the 2-sided 95% CI fell within (-14%, 14%). Non-responder imputation was applied. Comparisons between treatments were computed as PF-06410293 versus Adalimumab-EU.

<b>Statistical analysis title</b>	Percentage difference with 90% CI
Comparison groups	Period 1: PF-06410293 v Period 1: Adalimumab-EU

Number of subjects included in analysis	597
Analysis specification	Pre-specified
Analysis type	equivalence <sup>[2]</sup>
Parameter estimate	Week 12 ACR20 response rate difference
Point estimate	-2.98
Confidence interval	
level	90 %
sides	2-sided
lower limit	-9.25
upper limit	3.28

Notes:

[2] - Confidence interval (CIs) calculated by the score statistic method were used for the inference of the equivalence for ACR20 at Week 12. Therapeutic equivalence could be established if 2-sided 90% CI fell within (-12%, 15%). Non-responder imputation was applied. Comparisons between treatments were computed as PF-06410293 versus Adalimumab-EU.

### Secondary: Number of Subjects With an American College of Rheumatology 20% (ACR20) Response at Other Time Points Other Than Week 12: Period 1

End point title	Number of Subjects With an American College of Rheumatology 20% (ACR20) Response at Other Time Points Other Than Week 12: Period 1
-----------------	--

End point description:

ACR20 is a categorical variable indicating a 20% or greater improvement in tender and swollen joint counts and 20% or greater improvement in 3 of the 5 other ACR-core set measures: patient's assessment of arthritis pain (PAAP); patient's global assessment of arthritis (PGA); physician's global assessment of arthritis (PGAA); high sensitivity C-reactive protein (hs-CRP); and Health Assessment Questionnaire - Disability Index (HAQ-DI). The analysis population included all subjects who were randomized to study treatment. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 2, 4, 6, 8, 18 and 26 (pre-dose)

End point values	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	300		
Units: subjects				
Week 2	93	96		
Week 4	154	157		
Week 6	182	179		
Week 8	206	204		
Week 18	232	221		
Week 26 (pre-dose)	248	234		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With an American College of Rheumatology 20%

**(ACR20) Response: Period 2**

End point title	Number of Subjects With an American College of Rheumatology 20% (ACR20) Response: Period 2
-----------------	--

End point description:

ACR20 is a categorical variable indicating a 20% or greater improvement in tender and swollen joint counts and 20% or greater improvement in 3 of the 5 other ACR-core set measures: patient's assessment of arthritis pain (PAAP); patient's global assessment of arthritis (PGA); physician's global assessment of arthritis (PGAA); high sensitivity C-reactive protein (hs-CRP); and Health Assessment Questionnaire - Disability Index (HAQ-DI). The analysis population included all subjects who completed the Period 2 randomization call. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 26, 30, 36, 44 and 52 (pre-dose)

<b>End point values</b>	Period 2: PF-06410293/PF-06410293	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	283	135	134	
Units: subjects				
Week 26	245	114	116	
Week 30	245	111	116	
Week 36	236	105	118	
Week 44	233	106	108	
Week 52 (pre-dose)	234	107	113	

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Number of Subjects With an American College of Rheumatology 20% (ACR20) Response: Period 3**

End point title	Number of Subjects With an American College of Rheumatology 20% (ACR20) Response: Period 3
-----------------	--

End point description:

ACR20 is a categorical variable indicating a 20% or greater improvement in tender and swollen joint counts and 20% or greater improvement in 3 of the 5 other ACR-core set measures: patient's assessment of arthritis pain (PAAP); patient's global assessment of arthritis (PGA); physician's global assessment of arthritis (PGAA); high sensitivity C-reactive protein (hs-CRP); and Health Assessment Questionnaire - Disability Index (HAQ-DI). The analysis population included all subjects enrolled in Period 3. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 52, 56, 66, 76 and 78

<b>End point values</b>	Period 3: PF-06410293/PF-06410293/PF-06410293	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293	Period 3: Adalimumab-EU/PF-06410293/PF-06410293	Period 3 Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	259	121	127	507
Units: subjects				
Week 52	229	106	112	447
Week 56	230	105	106	441
Week 66	226	103	108	437
Week 76	219	95	106	420
Week 78	216	102	109	427

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With an American College of Rheumatology 50% (ACR50) Response: Period 1

End point title	Number of Subjects With an American College of Rheumatology 50% (ACR50) Response: Period 1
-----------------	--

End point description:

ACR50 is a categorical variable indicating a 50% or greater improvement in tender and swollen joint counts and 50% or greater improvement in 3 of the 5 other ACR-core set measures: patient's assessment of arthritis pain (PAAP); patient's global assessment of arthritis (PGA); physician's global assessment of arthritis (PGAA); high sensitivity C-reactive protein (hs-CRP); and Health Assessment Questionnaire - Disability Index (HAQ-DI). The analysis population included all subjects who were randomized to study treatment. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 2, 4, 6, 8, 12, 18 and 26 (pre-dose)

<b>End point values</b>	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	300		
Units: subjects				
Week 2	25	18		
Week 4	53	43		
Week 6	82	82		
Week 8	101	100		
Week 12	118	119		
Week 18	134	141		
Week 26 (pre-dose)	177	164		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With an American College of Rheumatology 50% (ACR50) Response: Period 2

End point title	Number of Subjects With an American College of Rheumatology 50% (ACR50) Response: Period 2
-----------------	--

End point description:

ACR50 is a categorical variable indicating a 50% or greater improvement in tender and swollen joint counts and 50% or greater improvement in 3 of the 5 other ACR-core set measures: patient's assessment of arthritis pain (PAAP); patient's global assessment of arthritis (PGA); physician's global assessment of arthritis (PGAA); high sensitivity C-reactive protein (hs-CRP); and Health Assessment Questionnaire - Disability Index (HAQ-DI). The analysis population included all subjects who completed the Period 2 randomization call. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 26, 30, 36, 44 and 52 (pre-dose)

End point values	Period 2: PF-06410293/PF-06410293	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	283	135	134	
Units: subjects				
Week 26	175	76	86	
Week 30	169	67	82	
Week 36	173	70	94	
Week 44	182	67	87	
Week 52 (pre-dose)	178	75	97	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With an American College of Rheumatology 50% (ACR50) Response: Period 3

End point title	Number of Subjects With an American College of Rheumatology 50% (ACR50) Response: Period 3
-----------------	--

End point description:

ACR50 is a categorical variable indicating a 50% or greater improvement in tender and swollen joint counts and 50% or greater improvement in 3 of the 5 other ACR-core set measures: patient's assessment of arthritis pain (PAAP); patient's global assessment of arthritis (PGA); physician's global assessment of arthritis (PGAA); high sensitivity C-reactive protein (hs-CRP); and Health Assessment Questionnaire - Disability Index (HAQ-DI). The analysis population included all subjects enrolled in Period 3. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 52, 56, 66, 76 and 78

<b>End point values</b>	Period 3: PF-06410293/PF-06410293/PF-06410293	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293	Period 3: Adalimumab-EU/PF-06410293/PF-06410293	Period 3 Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	259	121	127	507
Units: subjects				
Week 52	177	74	96	347
Week 56	175	78	94	347
Week 66	177	75	92	344
Week 76	179	66	90	335
Week 78	185	71	90	346

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With an American College of Rheumatology 70% (ACR70) Response: Period 1

End point title	Number of Subjects With an American College of Rheumatology 70% (ACR70) Response: Period 1
-----------------	--

End point description:

ACR70 is a categorical variable indicating a 70% or greater improvement in tender and swollen joint counts and 70% or greater improvement in 3 of the 5 other ACR-core set measures: patient's assessment of arthritis pain (PAAP); patient's global assessment of arthritis (PGA); physician's global assessment of arthritis (PGAA); high sensitivity C-reactive protein (hs-CRP); and Health Assessment Questionnaire - Disability Index (HAQ-DI). The analysis population included all subjects who were randomized to study treatment. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 2, 4, 6, 8, 12, 18 and 26 (pre-dose)

<b>End point values</b>	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	300		
Units: subjects				
Week 2	2	6		
Week 4	11	11		
Week 6	24	26		
Week 8	37	35		
Week 12	49	57		
Week 18	64	66		
Week 26 (pre-dose)	88	93		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With an American College of Rheumatology 70% (ACR70) Response: Period 2

End point title	Number of Subjects With an American College of Rheumatology 70% (ACR70) Response: Period 2
-----------------	--

End point description:

ACR70 is a categorical variable indicating a 70% or greater improvement in tender and swollen joint counts and 70% or greater improvement in 3 of the 5 other ACR-core set measures: patient's assessment of arthritis pain (PAAP); patient's global assessment of arthritis (PGA); physician's global assessment of arthritis (PGAA); high sensitivity C-reactive protein (hs-CRP); and Health Assessment Questionnaire - Disability Index (HAQ-DI). The analysis population included all subjects who completed the Period 2 randomization call. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 26, 30, 36, 44 and 52 (pre-dose)

End point values	Period 2: PF-06410293/PF-06410293	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	283	135	134	
Units: subjects				
Week 26	88	41	52	
Week 30	96	41	49	
Week 36	102	36	59	
Week 44	109	44	53	
Week 52 (pre-dose)	103	43	59	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With an American College of Rheumatology 70% (ACR70) Response: Period 3

End point title	Number of Subjects With an American College of Rheumatology 70% (ACR70) Response: Period 3
-----------------	--

End point description:

ACR70 is a categorical variable indicating a 70% or greater improvement in tender and swollen joint counts and 70% or greater improvement in 3 of the 5 other ACR-core set measures: patient's assessment of arthritis pain (PAAP); patient's global assessment of arthritis (PGA); physician's global

assessment of arthritis (PGAA); high sensitivity C-reactive protein (hs-CRP); and Health Assessment Questionnaire - Disability Index (HAQ-DI). The analysis population included all subjects enrolled in Period 3. Not all subjects had data for each visit.

End point type	Secondary
End point timeframe:	
Weeks 52, 56, 66, 76 and 78	

End point values	Period 3: PF-06410293/PF-06410293/PF-06410293	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293	Period 3: Adalimumab-EU/PF-06410293/PF-06410293	Period 3 Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	259	121	127	507
Units: subjects				
Week 52	103	42	58	203
Week 56	101	42	59	202
Week 66	112	48	60	220
Week 76	118	39	63	220
Week 78	128	48	69	245

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Tender Joint Count: Period 1

End point title	Change From Baseline in Tender Joint Count: Period 1
End point description:	
<p>Sixty-eight (68) joints were assessed by an independent blinded joint assessor to determine the number of joints that were considered tender. The 68 joints assessed were: upper body including temporomandibular, sternoclavicular, acromioclavicular; upper extremity including shoulder, elbow, wrist (radiocarpal, carpal and carpometacarpal considered as 1 unit), metacarpophalangeals (MCP I, II, III, IV, V), thumb interphalangeal, proximal interphalangeals (PIP II, III, IV, V), and distal interphalangeals (DIP II, III, IV, V); lower extremity including hip, knee, ankle, tarsus (subtalar, transverse tarsal and tarsometatarsal considered as 1 unit), metatarsophalangeals (MTP I, II, III, IV, V), great toe interphalangeal, proximal and distal interphalangeals combined (PIP and DIP II, III, IV, V). The analysis population included all subjects who were randomized to study treatment. Not all subjects had data for each visit.</p>	
End point type	Secondary
End point timeframe:	
Baseline, Weeks 2, 4, 6, 8, 12, 18 and 26 (pre-dose)	

End point values	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	300		
Units: joints				
arithmetic mean (standard deviation)				
Baseline	24.3 (± 12.29)	26.7 (± 14.80)		
Change at Week 2	-7.5 (± 9.89)	-7.1 (± 9.14)		
Change at Week 4	-10.2 (± 10.59)	-10.7 (± 9.92)		
Change at Week 6	-12.8 (± 11.28)	-13.1 (± 11.93)		
Change at Week 8	-14.2 (± 11.37)	-15.2 (± 11.84)		
Change at Week 12	-15.4 (± 11.69)	-16.1 (± 12.65)		
Change at Week 18	-16.8 (± 11.42)	-17.3 (± 12.69)		
Change at Week 26 (pre-dose)	-18.4 (± 11.41)	-19.2 (± 12.52)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Tender Joint Count: Period 2

End point title	Change From Baseline in Tender Joint Count: Period 2
End point description:	Sixty-eight (68) joints were assessed by an independent blinded joint assessor to determine the number of joints that were considered tender. The 68 joints assessed were: upper body including temporomandibular, sternoclavicular, acromioclavicular; upper extremity including shoulder, elbow, wrist (radiocarpal, carpal and carpometacarpal considered as 1 unit), metacarpophalangeals (MCP I, II, III, IV, V), thumb interphalangeal, proximal interphalangeals (PIP II, III, IV, V), and distal interphalangeals (DIP II, III, IV, V); lower extremity including hip, knee, ankle, tarsus (subtalar, transverse tarsal and tarsometatarsal considered as 1 unit), metatarsophalangeals (MTP I, II, III, IV, V), great toe interphalangeal, proximal and distal interphalangeals combined (PIP and DIP II, III, IV, V). The analysis population included all subjects who completed the Period 2 randomization call. Not all subjects had data for each visit.
End point type	Secondary
End point timeframe:	Baseline, Weeks 26, 30, 36, 44 and 52 (pre-dose)

End point values	Period 2: PF-06410293/PF-06410293	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	283	135	134	
Units: joints				
arithmetic mean (standard deviation)				
Baseline	23.7 (± 11.87)	26.8 (± 14.72)	25.5 (± 15.00)	

Change at Week 26	-18.4 (± 11.34)	-20.1 (± 12.47)	-19.3 (± 11.99)	
Change at Week 30	-19.0 (± 11.85)	-19.5 (± 14.28)	-19.4 (± 12.22)	
Change at Week 36	-18.7 (± 12.01)	-20.1 (± 12.62)	-20.4 (± 12.56)	
Change at Week 44	-19.4 (± 12.01)	-21.5 (± 13.56)	-20.2 (± 12.94)	
Change at Week 52 (pre-dose)	-18.9 (± 11.49)	-21.0 (± 14.14)	-21.2 (± 12.95)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Tender Joint Count: Period 3

End point title	Change From Baseline in Tender Joint Count: Period 3
-----------------	--

End point description:

Sixty-eight (68) joints were assessed by an independent blinded joint assessor to determine the number of joints that were considered tender. The 68 joints assessed were: upper body including temporomandibular, sternoclavicular, acromioclavicular; upper extremity including shoulder, elbow, wrist (radiocarpal, carpal and carpometacarpal considered as 1 unit), metacarpophalangeals (MCP I, II, III, IV, V), thumb interphalangeal, proximal interphalangeals (PIP II, III, IV, V), and distal interphalangeals (DIP II, III, IV, V); lower extremity including hip, knee, ankle, tarsus (subtalar, transverse tarsal and tarsometatarsal considered as 1 unit), metatarsophalangeals (MTP I, II, III, IV, V), great toe interphalangeal, proximal and distal interphalangeals combined (PIP and DIP II, III, IV, V). The analysis population included all subjects enrolled in Period 3. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 52, 56, 66, 76 and 78

End point values	Period 3: PF-06410293/PF-06410293/PF-06410293	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293	Period 3: Adalimumab-EU/PF-06410293/PF-06410293	Period 3 Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	259	121	127	507
Units: joints				
arithmetic mean (standard deviation)				
Baseline	23.8 (± 11.89)	26.5 (± 14.97)	25.4 (± 14.77)	24.9 (± 13.45)
Change at Week 52	-19.3 (± 11.38)	-21.2 (± 14.13)	-21.2 (± 13.00)	-20.2 (± 12.50)
Change at Week 56	-19.4 (± 11.27)	-21.1 (± 13.55)	-21.6 (± 13.43)	-20.4 (± 12.42)
Change at Week 66	-19.5 (± 10.97)	-21.3 (± 12.83)	-21.6 (± 13.55)	-20.5 (± 12.12)
Change at Week 76	-20.6 (± 11.75)	-22.0 (± 14.06)	-22.0 (± 14.00)	-21.3 (± 12.89)
Change at Week 78	-20.5 (± 11.53)	-21.1 (± 13.23)	-22.1 (± 14.26)	-21.1 (± 12.67)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Swollen Joint Count: Period 1

End point title Change From Baseline in Swollen Joint Count: Period 1

End point description:

Sixty-six (66) joints were assessed for swelling, the same as those listed for tender joint count, excluding the right and left hip joints. The analysis population included all subjects who were randomized to study treatment. Not all subjects had data for each visit.

End point type Secondary

End point timeframe:

Baseline, Weeks 2, 4, 6, 8, 12, 18 and 26 (pre-dose)

End point values	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	300		
Units: joints				
arithmetic mean (standard deviation)				
Baseline	15.4 (± 7.81)	17.0 (± 9.86)		
Change at Week 2	-5.7 (± 6.31)	-6.1 (± 7.23)		
Change at Week 4	-7.7 (± 7.04)	-8.2 (± 8.38)		
Change at Week 6	-9.0 (± 7.37)	-9.7 (± 8.97)		
Change at Week 8	-9.8 (± 7.06)	-11.0 (± 8.50)		
Change at Week 12	-10.4 (± 7.38)	-11.8 (± 8.87)		
Change at Week 18	-11.3 (± 6.76)	-13.0 (± 9.45)		
Change at Week 26 (pre-dose)	-12.2 (± 7.18)	-13.6 (± 9.12)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Swollen Joint Count: Period 2

End point title Change From Baseline in Swollen Joint Count: Period 2

End point description:

Sixty-six (66) joints were assessed for swelling, the same as those listed for tender joint count, excluding the right and left hip joints. The analysis population included all subjects who completed the Period 2 randomization call. Not all subjects had data for each visit.

End point type Secondary

End point timeframe:

Baseline, Weeks 26, 30, 36, 44 and 52 (pre-dose)

<b>End point values</b>	Period 2: PF-06410293/PF-06410293	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	283	135	134	
Units: joints				
arithmetic mean (standard deviation)				
Baseline	15.1 (± 7.66)	17.1 (± 9.60)	17.0 (± 10.31)	
Change at Week 26	-12.2 (± 7.11)	-13.6 (± 8.15)	-14.3 (± 9.84)	
Change at Week 30	-12.3 (± 7.58)	-13.3 (± 9.31)	-14.3 (± 9.70)	
Change at Week 36	-12.4 (± 7.76)	-14.2 (± 8.74)	-14.6 (± 9.69)	
Change at Week 44	-12.8 (± 7.12)	-14.7 (± 8.87)	-14.8 (± 9.97)	
Change at Week 52 (pre-dose)	-12.6 (± 6.92)	-14.2 (± 8.29)	-15.2 (± 9.82)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Swollen Joint Count: Period 3

End point title	Change From Baseline in Swollen Joint Count: Period 3
End point description:	Sixty-six (66) joints were assessed for swelling, the same as those listed for tender joint count, excluding the right and left hip joints. The analysis population included all subjects enrolled in Period 3. Not all subjects had data for each visit.
End point type	Secondary
End point timeframe:	Baseline, Weeks 52, 56, 66, 76 and 78

<b>End point values</b>	Period 3: PF-06410293/PF-06410293/PF-06410293	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293	Period 3: Adalimumab-EU/PF-06410293/PF-06410293	Period 3 Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	259	121	127	507
Units: joints				
arithmetic mean (standard deviation)				
Baseline	15.0 (± 7.59)	17.3 (± 9.77)	16.8 (± 10.07)	16.0 (± 8.85)
Change at Week 52	-12.8 (± 6.87)	-14.4 (± 8.22)	-15.2 (± 9.75)	-13.7 (± 8.05)
Change at Week 56	-12.9 (± 6.61)	-14.5 (± 8.65)	-14.9 (± 9.65)	-13.8 (± 8.00)
Change at Week 66	-13.0 (± 7.09)	-14.9 (± 8.37)	-15.2 (± 9.92)	-14.0 (± 8.23)

Change at Week 76	-13.3 (± 7.12)	-14.9 (± 8.86)	-15.1 (± 10.27)	-14.1 (± 8.44)
Change at Week 78	-13.4 (± 7.25)	-15.0 (± 9.35)	-15.1 (± 10.24)	-14.2 (± 8.63)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Physician's Global Assessment of Arthritis (PGAA): Period 1

End point title	Change From Baseline in Physician's Global Assessment of Arthritis (PGAA): Period 1
-----------------	---

End point description:

The investigator assessed how the subject's overall arthritis appeared at the time of the visit. This was an evaluation based on the subject's disease symptoms, functional capacity and physical examination, and independent of the subject's reported assessments of PGA (patient's global assessment of arthritis) and PAAP (patient's assessment of arthritis pain). The investigator's response was recorded using a 100 mm visual analog scale (VAS), with the 0 mm end labeled "None" and the 100 mm end labeled "Extreme". The analysis population included all subjects who were randomized to study treatment. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, 6, 8, 12, 18 and 26 (pre-dose)

End point values	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	300		
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline	65.0 (± 15.22)	66.7 (± 15.80)		
Change at Week 2	-20.7 (± 18.62)	-20.5 (± 18.87)		
Change at Week 4	-28.9 (± 20.24)	-29.0 (± 18.29)		
Change at Week 6	-32.6 (± 21.72)	-33.0 (± 19.87)		
Change at Week 8	-35.6 (± 20.86)	-37.1 (± 18.97)		
Change at Week 12	-40.4 (± 19.01)	-40.5 (± 19.45)		
Change at Week 18	-44.2 (± 18.96)	-44.2 (± 19.64)		
Change at Week 26 (pre-dose)	-47.2 (± 18.68)	-46.5 (± 19.96)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Physician's Global Assessment of Arthritis (PGAA): Period 2

End point title	Change From Baseline in Physician's Global Assessment of Arthritis (PGAA): Period 2
-----------------	---

End point description:

The investigator assessed how the subject's overall arthritis appeared at the time of the visit. This was an evaluation based on the subject's disease symptoms, functional capacity and physical examination, and independent of the subject's reported assessments of PGA (patient's global assessment of arthritis) and PAAP (patient's assessment of arthritis pain). The investigator's response was recorded using a 100 mm visual analog scale (VAS), with the 0 mm end labeled "None" and the 100 mm end labeled "Extreme". The analysis population included all subjects who completed the Period 2 randomization call. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 26, 30, 36, 44 and 52 (pre-dose)

End point values	Period 2: PF-06410293/PF-06410293	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	283	135	134	
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline	64.9 (± 15.21)	66.3 (± 15.34)	67.0 (± 15.56)	
Change at Week 26	-47.7 (± 18.09)	-45.5 (± 19.80)	-49.2 (± 18.77)	
Change at Week 30	-47.9 (± 20.02)	-46.5 (± 19.52)	-49.6 (± 18.53)	
Change at Week 36	-47.3 (± 20.22)	-45.4 (± 19.46)	-49.5 (± 20.47)	
Change at Week 44	-49.1 (± 18.34)	-46.9 (± 20.16)	-50.5 (± 20.50)	
Change at Week 52 (pre-dose)	-47.9 (± 18.89)	-48.4 (± 17.75)	-52.1 (± 20.01)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Physician's Global Assessment of Arthritis (PGAA): Period 3

End point title	Change From Baseline in Physician's Global Assessment of Arthritis (PGAA): Period 3
-----------------	---

End point description:

The investigator assessed how the subject's overall arthritis appeared at the time of the visit. This was an evaluation based on the subject's disease symptoms, functional capacity and physical examination, and independent of the subject's reported assessments of PGA (patient's global assessment of arthritis) and PAAP (patient's assessment of arthritis pain). The investigator's response was recorded using a 100 mm visual analog scale (VAS), with the 0 mm end labeled "None" and the 100 mm end labeled

“Extreme”. The analysis population included all subjects enrolled in period 3. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 52, 56, 66, 76 and 78

<b>End point values</b>	Period 3: PF-06410293/PF-06410293/PF-06410293	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293	Period 3: Adalimumab-EU/PF-06410293/PF-06410293	Period 3 Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	259	121	127	507
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline	65.4 (± 14.57)	66.4 (± 15.55)	67.0 (± 15.73)	66.1 (± 15.09)
Change at Week 52	-48.9 (± 17.82)	-48.5 (± 17.87)	-52.2 (± 19.62)	-49.7 (± 18.33)
Change at Week 56	-50.5 (± 16.95)	-47.7 (± 20.00)	-51.6 (± 21.18)	-50.1 (± 18.85)
Change at Week 66	-49.4 (± 18.93)	-49.1 (± 18.21)	-51.1 (± 20.29)	-49.8 (± 19.09)
Change at Week 76	-50.9 (± 17.87)	-49.7 (± 21.07)	-52.3 (± 20.57)	-51.0 (± 19.33)
Change at Week 78	-52.3 (± 17.40)	-50.8 (± 19.42)	-52.5 (± 19.96)	-52.0 (± 18.55)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Patient’s Assessment of Arthritis Pain (PAAP): Period 1

End point title	Change From Baseline in Patient’s Assessment of Arthritis Pain (PAAP): Period 1
-----------------	---

End point description:

Subjects assessed the severity of their arthritis pain using a 100 mm Visual Analog Scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain. The analysis population included all subjects who were randomized to study treatment. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, 6, 8, 12, 18 and 26 (pre-dose)

<b>End point values</b>	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	300		
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline	63.7 (± 18.42)	65.9 (± 19.61)		
Change at Week 2	-13.1 (± 18.59)	-13.9 (± 18.72)		
Change at Week 4	-18.5 (± 20.35)	-17.4 (± 20.30)		
Change at Week 6	-21.9 (± 21.92)	-21.7 (± 22.49)		
Change at Week 8	-24.8 (± 24.06)	-25.5 (± 23.18)		
Change at Week 12	-28.8 (± 24.80)	-28.5 (± 23.91)		
Change at Week 18	-31.5 (± 23.69)	-31.4 (± 25.48)		
Change at Week 26 (pre-dose)	-35.1 (± 24.62)	-33.5 (± 26.09)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP): Period 2

End point title	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP): Period 2
End point description:	Subjects assessed the severity of their arthritis pain using a 100 mm Visual Analog Scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain. The analysis population included all subjects who completed the Period 2 randomization call. Not all subjects had data for each visit.
End point type	Secondary
End point timeframe:	Baseline, Weeks 26, 30, 36, 44 and 52 (pre-dose)

<b>End point values</b>	Period 2: PF-06410293/PF-06410293	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	283	135	134	
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline	63.5 (± 18.04)	65.6 (± 19.91)	64.4 (± 19.37)	
Change at Week 26	-35.4 (± 23.87)	-32.4 (± 25.68)	-36.0 (± 26.04)	

Change at Week 30	-36.3 (± 24.86)	-34.1 (± 26.40)	-37.6 (± 24.47)	
Change at Week 36	-35.5 (± 25.87)	-34.9 (± 25.74)	-39.4 (± 24.87)	
Change at Week 44	-38.6 (± 25.03)	-35.7 (± 26.16)	-38.3 (± 28.05)	
Change at Week 52 (pre-dose)	-37.4 (± 25.09)	-36.8 (± 24.05)	-40.6 (± 24.16)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP): Period 3

End point title	Change From Baseline in Patient's Assessment of Arthritis Pain (PAAP): Period 3
End point description:	Subjects assessed the severity of their arthritis pain using a 100 mm Visual Analog Scale (VAS) by placing a mark on the scale between 0 (no pain) and 100 (most severe pain), which corresponded to the magnitude of their pain. The analysis population included all subjects enrolled in Period 3. Not all subjects had data for each visit.
End point type	Secondary
End point timeframe:	Baseline, Weeks 52, 56, 66, 76 and 78

End point values	Period 3: PF-06410293/PF-06410293/PF-06410293	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293	Period 3: Adalimumab-EU/PF-06410293/PF-06410293	Period 3 Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	259	121	127	507
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline	63.5 (± 17.99)	66.3 (± 19.98)	64.5 (± 19.05)	64.4 (± 18.75)
Change at Week 52	-38.1 (± 25.06)	-37.3 (± 23.93)	-40.6 (± 23.96)	-38.5 (± 24.50)
Change at Week 56	-39.1 (± 23.87)	-37.7 (± 25.07)	-40.1 (± 25.62)	-39.0 (± 24.57)
Change at Week 66	-39.8 (± 24.74)	-39.2 (± 24.76)	-40.7 (± 26.42)	-39.9 (± 25.13)
Change at Week 76	-41.3 (± 25.60)	-39.3 (± 25.95)	-42.4 (± 25.68)	-41.1 (± 25.67)
Change at Week 78	-43.7 (± 25.17)	-41.4 (± 25.04)	-42.7 (± 26.09)	-42.9 (± 25.34)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Patient's Global Assessment of Arthritis (PGA): Period 1

End point title Change From Baseline in Patient's Global Assessment of Arthritis (PGA): Period 1

End point description:

Subjects answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The subject's response was recorded using a 100 mm visual analog scale (VAS), with the 0 mm end labeled "Very Well" and the 100 mm end labeled "Very Poorly". The analysis population included all subjects who were randomized to study treatment. Not all subjects had data for each visit.

End point type Secondary

End point timeframe:

Baseline, Weeks 2, 4, 6, 8, 12, 18 and 26 (pre-dose)

End point values	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	300		
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline	64.4 (± 19.32)	68.1 (± 19.49)		
Change at Week 2	-13.8 (± 19.03)	-16.3 (± 18.30)		
Change at Week 4	-19.7 (± 20.85)	-21.2 (± 21.62)		
Change at Week 6	-22.2 (± 22.96)	-23.4 (± 22.69)		
Change at Week 8	-25.8 (± 24.01)	-28.4 (± 23.17)		
Change at Week 12	-29.3 (± 24.72)	-31.5 (± 24.36)		
Change at Week 18	-32.2 (± 24.57)	-34.2 (± 25.94)		
Change at Week 26 (pre-dose)	-36.2 (± 25.16)	-36.3 (± 26.21)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Patient's Global Assessment of Arthritis (PGA): Period 2

End point title Change From Baseline in Patient's Global Assessment of Arthritis (PGA): Period 2

End point description:

Subjects answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The subject's response was recorded using a 100 mm visual analog scale (VAS), with the 0 mm end labeled "Very Well" and the 100 mm end labeled "Very Poorly". The analysis population included all subjects who completed the Period 2 randomization call. Not all subjects had

data for each visit.

End point type	Secondary
End point timeframe:	
Baseline, Weeks 26, 30, 36, 44 and 52 (pre-dose)	

End point values	Period 2: PF-06410293/PF-06410293	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	283	135	134	
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline	64.2 (± 19.05)	67.5 (± 21.02)	67.8 (± 17.59)	
Change at Week 26	-36.3 (± 24.47)	-35.3 (± 26.02)	-38.8 (± 25.71)	
Change at Week 30	-36.7 (± 26.11)	-35.5 (± 27.02)	-41.2 (± 22.34)	
Change at Week 36	-36.4 (± 26.51)	-36.0 (± 26.30)	-43.1 (± 22.31)	
Change at Week 44	-39.4 (± 25.01)	-36.7 (± 25.43)	-40.6 (± 26.49)	
Change at Week 52 (pre-dose)	-37.5 (± 25.88)	-38.6 (± 24.97)	-44.0 (± 22.94)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Patient's Global Assessment of Arthritis (PGA): Period 3

End point title	Change From Baseline in Patient's Global Assessment of Arthritis (PGA): Period 3
-----------------	--

End point description:

Subjects answered the following question, "Considering all the ways your arthritis affects you, how are you feeling today?" The subject's response was recorded using a 100 mm visual analog scale (VAS), with the 0 mm end labeled "Very Well" and the 100 mm end labeled "Very Poorly". The analysis population included all subjects enrolled in Period 3. Not all subjects had data for each visit.

End point type	Secondary
End point timeframe:	
Baseline, Weeks 52, 56, 66, 76 and 78	

<b>End point values</b>	Period 3: PF-06410293/PF-06410293/PF-06410293	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293	Period 3: Adalimumab-EU/PF-06410293/PF-06410293	Period 3 Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	259	121	127	507
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline	64.1 (± 19.02)	67.5 (± 21.04)	68.1 (± 17.30)	65.9 (± 19.17)
Change at Week 52	-38.3 (± 25.54)	-39.0 (± 24.94)	-43.9 (± 22.79)	-39.9 (± 24.80)
Change at Week 56	-39.7 (± 24.47)	-39.1 (± 25.61)	-43.4 (± 25.16)	-40.5 (± 24.93)
Change at Week 66	-40.6 (± 25.04)	-39.7 (± 24.43)	-43.3 (± 26.63)	-41.1 (± 25.29)
Change at Week 76	-41.7 (± 26.94)	-40.5 (± 26.56)	-45.3 (± 23.51)	-42.3 (± 26.05)
Change at Week 78	-43.8 (± 26.05)	-42.0 (± 25.09)	-45.4 (± 24.61)	-43.8 (± 25.44)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI): Period 1

End point title	Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI): Period 1
-----------------	---

End point description:

HAQ-DI assesses the degree of difficulty a subject had experienced during the past week in 8 domains of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each activity category consisted of 2-3 items. For each question in the questionnaire, the level of difficulty was scored from 0 to 3 with 0 representing "no difficulty", 1 as "some difficulty", 2 as "much difficulty", and 3 as "unable to do". Any activity that required assistance from another individual or required the use of an assistive device would adjust to a minimum score of 2 to represent a more limited functional status. Overall score was sum of scores for each domain. Higher score indicate more difficulty in performing daily living activities. The analysis population included all subjects who were randomized to study treatment. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, 6, 8, 12, 18 and 26 (pre-dose)

<b>End point values</b>	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	300		
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline	1.519 (± 0.6009)	1.673 (± 0.6378)		

Change at Week 2	-0.254 (± 0.4018)	-0.288 (± 0.4383)		
Change at Week 4	-0.338 (± 0.4720)	-0.375 (± 0.4555)		
Change at Week 6	-0.426 (± 0.5114)	-0.454 (± 0.5350)		
Change at Week 8	-0.480 (± 0.5253)	-0.520 (± 0.5457)		
Change at Week 12	-0.530 (± 0.5218)	-0.543 (± 0.5882)		
Change at Week 18	-0.583 (± 0.5704)	-0.630 (± 0.6344)		
Change at Week 26 (pre-dose)	-0.654 (± 0.6262)	-0.674 (± 0.6618)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI): Period 2

End point title	Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI): Period 2
-----------------	---

End point description:

HAQ-DI assesses the degree of difficulty a subject had experienced during the past week in 8 domains of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each activity category consisted of 2-3 items. For each question in the questionnaire, the level of difficulty was scored from 0 to 3 with 0 representing "no difficulty", 1 as "some difficulty", 2 as "much difficulty", and 3 as "unable to do". Any activity that required assistance from another individual or required the use of an assistive device would adjust to a minimum score of 2 to represent a more limited functional status. Overall score was sum of scores for each domain. Higher score indicate more difficulty in performing daily living activities. The analysis population included all subjects who completed the Period 2 randomization call. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 26, 30, 36, 44 and 52 (pre-dose)

End point values	Period 2: PF-06410293/PF-06410293	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	283	135	134	
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline	1.514 (± 0.5920)	1.639 (± 0.6677)	1.666 (± 0.6271)	
Change at Week 26	-0.658 (± 0.6250)	-0.652 (± 0.6293)	-0.723 (± 0.6763)	
Change at Week 30	-0.681 (± 0.6379)	-0.650 (± 0.6673)	-0.772 (± 0.7113)	
Change at Week 36	-0.711 (± 0.6585)	-0.662 (± 0.6610)	-0.811 (± 0.7048)	

Change at Week 44	-0.726 ( $\pm$ 0.6605)	-0.690 ( $\pm$ 0.6414)	-0.834 ( $\pm$ 0.6956)	
Change at Week 52 (pre-dose)	-0.700 ( $\pm$ 0.6776)	-0.729 ( $\pm$ 0.6359)	-0.840 ( $\pm$ 0.6861)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI): Period 3

End point title	Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI): Period 3
-----------------	---

End point description:

HAQ-DI assesses the degree of difficulty a subject had experienced during the past week in 8 domains of daily activities: dressing and grooming, arising, eating, walking, hygiene, reach, grip and other activities. Each activity category consisted of 2-3 items. For each question in the questionnaire, the level of difficulty was scored from 0 to 3 with 0 representing "no difficulty", 1 as "some difficulty", 2 as "much difficulty", and 3 as "unable to do". Any activity that required assistance from another individual or required the use of an assistive device would adjust to a minimum score of 2 to represent a more limited functional status. Overall score was sum of scores for each domain. Higher score indicate more difficulty in performing daily living activities. The analysis population included all subjects enrolled in Period 3. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 52, 56, 66, 76 and 78

End point values	Period 3: PF-06410293/PF-06410293/PF-06410293	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293	Period 3: Adalimumab-EU/PF-06410293/PF-06410293	Period 3 Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	259	121	127	507
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline	1.528 ( $\pm$ 0.5941)	1.632 ( $\pm$ 0.6711)	1.684 ( $\pm$ 0.6164)	1.592 ( $\pm$ 0.6212)
Change at Week 52	-0.719 ( $\pm$ 0.6809)	-0.737 ( $\pm$ 0.6379)	-0.836 ( $\pm$ 0.6877)	-0.752 ( $\pm$ 0.6731)
Change at Week 56	-0.735 ( $\pm$ 0.6733)	-0.754 ( $\pm$ 0.6149)	-0.801 ( $\pm$ 0.6549)	-0.756 ( $\pm$ 0.6543)
Change at Week 66	-0.731 ( $\pm$ 0.6656)	-0.731 ( $\pm$ 0.6493)	-0.828 ( $\pm$ 0.6872)	-0.755 ( $\pm$ 0.6672)
Change at Week 76	-0.751 ( $\pm$ 0.6725)	-0.789 ( $\pm$ 0.7225)	-0.867 ( $\pm$ 0.7066)	-0.788 ( $\pm$ 0.6931)
Change at Week 78	-0.781 ( $\pm$ 0.6571)	-0.800 ( $\pm$ 0.7240)	-0.881 ( $\pm$ 0.7194)	-0.811 ( $\pm$ 0.6894)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in High-Sensitivity C-Reactive Protein (hs-CRP): Period 1

End point title	Change From Baseline in High-Sensitivity C-Reactive Protein (hs-CRP): Period 1
-----------------	--

End point description:

Serum samples were analyzed to determine the level of hs-CRP, which was an acute-phase reactant. The analysis population included all subjects who were randomized to study treatment. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 1, 2, 4, 6, 8, 12, 18 and 26 (pre-dose)

End point values	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	300		
Units: mg/L				
arithmetic mean (standard deviation)				
Baseline	21.3 (± 22.69)	22.8 (± 25.26)		
Change at Week 1	-12.6 (± 19.84)	-13.4 (± 24.83)		
Change at Week 2	-11.5 (± 19.10)	-13.1 (± 20.74)		
Change at Week 4	-11.2 (± 19.94)	-12.6 (± 23.16)		
Change at Week 6	-11.3 (± 18.73)	-12.6 (± 24.74)		
Change at Week 8	-9.1 (± 22.65)	-12.0 (± 25.68)		
Change at Week 12	-9.5 (± 22.81)	-12.2 (± 25.59)		
Change at Week 18	-11.4 (± 20.67)	-12.3 (± 26.93)		
Change at Week 26 (pre-dose)	-11.1 (± 21.92)	-13.6 (± 26.47)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in High-Sensitivity C-Reactive Protein (hs-CRP): Period 2

End point title	Change From Baseline in High-Sensitivity C-Reactive Protein (hs-CRP): Period 2
-----------------	--

End point description:

Serum samples were analyzed to determine the level of hs-CRP, which was an acute-phase reactant. The analysis population included all subjects who completed the Period 2 randomization call. Not all subjects had data for each visit.

End point type	Secondary
End point timeframe:	
Baseline, Weeks 26, 30, 36, 44 and 52 (pre-dose)	

End point values	Period 2: PF-06410293/PF-06410293	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	283	135	134	
Units: mg/L				
arithmetic mean (standard deviation)				
Baseline	21.2 (± 22.47)	22.0 (± 24.51)	22.3 (± 25.93)	
Change at Week 26	-11.3 (± 21.70)	-11.2 (± 27.76)	-15.8 (± 25.10)	
Change at Week 30	-11.3 (± 19.76)	-10.4 (± 26.85)	-15.0 (± 24.50)	
Change at Week 36	-10.6 (± 22.58)	-11.8 (± 25.41)	-12.5 (± 30.36)	
Change at Week 44	-9.9 (± 22.08)	-11.1 (± 27.01)	-14.8 (± 26.80)	
Change at Week 52 (pre-dose)	-10.6 (± 20.84)	-11.8 (± 23.85)	-12.8 (± 28.49)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in High-Sensitivity C-Reactive Protein (hs-CRP): Period 3

End point title	Change From Baseline in High-Sensitivity C-Reactive Protein (hs-CRP): Period 3
End point description:	
Serum samples were analyzed to determine the level of hs-CRP, which was an acute-phase reactant. The analysis population included all subjects enrolled in Period 3. Not all subjects had data for each visit.	
End point type	Secondary
End point timeframe:	
Baseline, Weeks 52, 56, 66, 76 and 78	

End point values	Period 3: PF-06410293/PF-06410293/PF-06410293	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293	Period 3: Adalimumab-EU/PF-06410293/PF-06410293	Period 3 Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	259	121	127	507
Units: mg/L				
arithmetic mean (standard deviation)				

Baseline	20.4 (± 20.43)	22.3 (± 25.30)	22.7 (± 26.49)	21.4 (± 23.25)
Change at Week 52	-10.7 (± 20.81)	-11.9 (± 24.04)	-12.9 (± 28.57)	-11.5 (± 23.70)
Change at Week 56	-9.9 (± 25.29)	-11.7 (± 26.66)	-14.3 (± 26.64)	-11.4 (± 25.97)
Change at Week 66	-11.1 (± 21.24)	-9.1 (± 25.83)	-13.2 (± 26.97)	-11.2 (± 23.87)
Change at Week 76	-12.1 (± 20.58)	-9.8 (± 22.03)	-11.9 (± 28.83)	-11.5 (± 23.15)
Change at Week 78	-9.7 (± 24.68)	-11.9 (± 22.90)	-13.3 (± 27.06)	-11.1 (± 24.90)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Disease Activity Score-28 (4 Components Based on High-Sensitivity C-Reactive Protein) (DAS28-4 [CRP]): Period 1

End point title	Change From Baseline in Disease Activity Score-28 (4 Components Based on High-Sensitivity C-Reactive Protein) (DAS28-4 [CRP]): Period 1
End point description:	The DAS assessment is a continuous composite measure derived using differential weighting given to each component. The components of the DAS28-4 (CRP) assessment included: tender joint count with 28 joints assessed, swollen joint count with 28 joints assessed, high-sensitivity C-reactive protein (hs-CRP) and patient's global assessment of arthritis (PGA). DAS28-4 (CRP) was calculated as 0.56 sqrt (DAS 28 tender joint count) + 0.28 sqrt (DAS 28 swollen joint count) + 0.36 ln(CRP [mg/L] + 1) + 0.014 (PGA [mm]) + 0.96. Higher score indicate more disease activity. The analysis population included all subjects who were randomized to study treatment. Not all subjects had data for each visit.
End point type	Secondary
End point timeframe:	Baseline, Weeks 2, 4, 6, 8, 12, 18 and 26 (pre-dose)

End point values	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	300		
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline	5.9 (± 0.87)	6.1 (± 0.90)		
Change at Week 2	-1.2 (± 0.91)	-1.1 (± 0.92)		
Change at Week 4	-1.5 (± 1.00)	-1.6 (± 1.01)		
Change at Week 6	-1.9 (± 1.19)	-1.9 (± 1.22)		
Change at Week 8	-2.0 (± 1.19)	-2.2 (± 1.22)		
Change at Week 12	-2.2 (± 1.20)	-2.3 (± 1.26)		
Change at Week 18	-2.5 (± 1.20)	-2.6 (± 1.33)		
Change at Week 26 (pre-dose)	-2.7 (± 1.18)	-2.8 (± 1.31)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Disease Activity Score-28 (4 Components Based on High-Sensitivity C-Reactive Protein) (DAS28-4 [CRP]): Period 2

End point title	Change From Baseline in Disease Activity Score-28 (4 Components Based on High-Sensitivity C-Reactive Protein) (DAS28-4 [CRP]): Period 2
-----------------	---

End point description:

The DAS assessment is a continuous composite measure derived using differential weighting given to each component. The components of the DAS28-4 (CRP) assessment included: tender joint count with 28 joints assessed, swollen joint count with 28 joints assessed, high-sensitivity C-reactive protein (hs-CRP) and patient's global assessment of arthritis (PGA). DAS28-4 (CRP) was calculated as  $0.56 \sqrt{\text{DAS 28 tender joint count}} + 0.28 \sqrt{\text{DAS 28 swollen joint count}} + 0.36 \ln(\text{CRP [mg/L]} + 1) + 0.014 (\text{PGA [mm]}) + 0.96$ . Higher score indicate more disease activity. The analysis population included all subjects who completed the Period 2 randomization call. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 26, 30, 36, 44 and 52 (pre-dose)

End point values	Period 2: PF-06410293/PF-06410293	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	283	135	134	
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline	5.9 (± 0.85)	6.1 (± 0.85)	6.0 (± 0.98)	
Change at Week 26	-2.7 (± 1.16)	-2.7 (± 1.28)	-3.0 (± 1.25)	
Change at Week 30	-2.8 (± 1.25)	-2.7 (± 1.31)	-3.1 (± 1.17)	
Change at Week 36	-2.8 (± 1.29)	-2.8 (± 1.32)	-3.1 (± 1.20)	
Change at Week 44	-3.0 (± 1.14)	-2.9 (± 1.26)	-3.2 (± 1.21)	
Change at Week 52 (pre-dose)	-2.9 (± 1.23)	-2.9 (± 1.33)	-3.3 (± 1.26)	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Disease Activity Score-28 (4 Components Based on High-Sensitivity C-Reactive Protein) (DAS28-4 [CRP]): Period 3

End point title	Change From Baseline in Disease Activity Score-28 (4
-----------------	--

End point description:

The DAS assessment is a continuous composite measure derived using differential weighting given to each component. The components of the DAS28-4 (CRP) assessment included: tender joint count with 28 joints assessed, swollen joint count with 28 joints assessed, high-sensitivity C-reactive protein (hs-CRP) and patient's global assessment of arthritis (PGA). DAS28-4 (CRP) was calculated as  $0.56 \sqrt{\text{DAS 28 tender joint count}} + 0.28 \sqrt{\text{DAS 28 swollen joint count}} + 0.36 \ln(\text{CRP [mg/L]} + 1) + 0.014 (\text{PGA [mm]}) + 0.96$ . Higher score indicate more disease activity. The analysis population included all subjects enrolled in Period 3. Not all subjects had data for each visit.

End point type Secondary

End point timeframe:

Baseline, Weeks 52, 56, 66, 76 and 78

End point values	Period 3: PF-06410293/PF-06410293	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293	Period 3: Adalimumab-EU/PF-06410293/PF-06410293	Period 3 Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	259	121	127	507
Units: units on a scale				
arithmetic mean (standard deviation)				
Baseline	5.9 (± 0.86)	6.1 (± 0.86)	6.0 (± 0.96)	6.0 (± 0.89)
Change at Week 52	-2.9 (± 1.21)	-2.9 (± 1.32)	-3.3 (± 1.25)	-3.0 (± 1.26)
Change at Week 56	-3.0 (± 1.22)	-2.9 (± 1.34)	-3.3 (± 1.29)	-3.0 (± 1.27)
Change at Week 66	-3.0 (± 1.19)	-3.0 (± 1.34)	-3.3 (± 1.26)	-3.1 (± 1.24)
Change at Week 76	-3.1 (± 1.18)	-3.0 (± 1.34)	-3.4 (± 1.29)	-3.2 (± 1.25)
Change at Week 78	-3.2 (± 1.21)	-3.1 (± 1.37)	-3.4 (± 1.39)	-3.2 (± 1.30)

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Number of Subjects Achieving European League Against Rheumatism (EULAR) Response: Period 1**

End point title Number of Subjects Achieving European League Against Rheumatism (EULAR) Response: Period 1

End point description:

EULAR response was based on DAS28 EULAR response criteria. Good response was achieved if DAS28 improvement from baseline  $>1.2$  and  $\text{DAS28} \leq 3.2$ . Moderate response was achieved if DAS28 improvement from baseline  $>0.6$  to  $\leq 1.2$  and  $\text{DAS28} \leq 5.1$ ; or DAS improvement from baseline  $>1.2$  and  $\text{DAS28} > 3.2$ . No response was achieved if DAS improvement from baseline  $\leq 0.6$  (no matter present DAS28 score); or DAS improvement from baseline  $>0.6$  to  $\leq 1.2$  and  $\text{DAS28} > 5.1$ . The analysis population included all subjects who were randomized to study treatment. Not all subjects had data for each visit.

End point type Secondary

End point timeframe:

Weeks 2, 4, 6, 8, 12, 18 and 26 (pre-dose)

<b>End point values</b>	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	300		
Units: subjects				
Week 2 good response	18	20		
Week 2 moderate response	161	136		
Week 2 no response	110	133		
Week 4 good response	48	42		
Week 4 moderate response	173	168		
Week 4 no response	71	81		
Week 6 good response	69	65		
Week 6 moderate response	178	173		
Week 6 no response	48	55		
Week 8 good response	93	89		
Week 8 moderate response	160	160		
Week 8 no response	38	43		
Week 12 good response	104	107		
Week 12 moderate response	149	149		
Week 12 no response	37	37		
Week 18 good response	137	132		
Week 18 moderate response	134	125		
Week 18 no response	21	29		
Week 26 (pre-dose) good response	162	147		
Week 26 (pre-dose) moderate response	110	102		
Week 26 (pre-dose) no response	16	27		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects Achieving European League Against Rheumatism (EULAR) Response: Period 2

End point title	Number of Subjects Achieving European League Against Rheumatism (EULAR) Response: Period 2
-----------------	--

End point description:

EULAR response was based on DAS28 EULAR response criteria. Good response was achieved if DAS28 improvement from baseline  $>1.2$  and  $\text{DAS28} \leq 3.2$ . Moderate response was achieved if  $\text{DAS28}$  improvement from baseline  $>0.6$  to  $\leq 1.2$  and  $\text{DAS28} \leq 5.1$ ; or  $\text{DAS}$  improvement from baseline  $>1.2$  and  $\text{DAS28} > 3.2$ . No response was achieved if  $\text{DAS}$  improvement from baseline  $\leq 0.6$  (no matter present  $\text{DAS28}$  score); or  $\text{DAS}$  improvement from baseline  $>0.6$  to  $\leq 1.2$  and  $\text{DAS28} > 5.1$ . The analysis population included all subjects who completed the Period 2 randomization call. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 26, 30, 36, 44 and 52 (pre-dose)

<b>End point values</b>	Period 2: PF-06410293/PF-06410293	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	283	135	134	
Units: subjects				
Week 26 good response	161	67	80	
Week 26 moderate response	109	53	45	
Week 26 no response	13	13	9	
Week 30 good response	160	64	83	
Week 30 moderate response	106	54	45	
Week 30 no response	13	12	3	
Week 36 good response	158	59	86	
Week 36 moderate response	97	60	39	
Week 36 no response	19	7	5	
Week 44 good response	170	62	83	
Week 44 moderate response	92	60	45	
Week 44 no response	5	3	2	
Week 52 (pre-dose) good response	169	61	85	
Week 52 (pre-dose) moderate response	86	54	40	
Week 52 (pre-dose) no response	12	8	2	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects Achieving European League Against Rheumatism (EULAR) Response: Period 3

End point title	Number of Subjects Achieving European League Against Rheumatism (EULAR) Response: Period 3
-----------------	--

End point description:

EULAR response was based on DAS28 EULAR response criteria. Good response was achieved if DAS28 improvement from baseline  $>1.2$  and  $\text{DAS28} \leq 3.2$ . Moderate response was achieved if DAS28 improvement from baseline  $>0.6$  to  $\leq 1.2$  and  $\text{DAS28} \leq 5.1$ ; or DAS improvement from baseline  $>1.2$  and  $\text{DAS28} > 3.2$ . No response was achieved if DAS improvement from baseline  $\leq 0.6$  (no matter present DAS28 score); or DAS improvement from baseline  $>0.6$  to  $\leq 1.2$  and  $\text{DAS28} > 5.1$ . The analysis population included all subjects enrolled in Period 3. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 52, 56, 66, 76 and 78

<b>End point values</b>	Period 3: PF-06410293/PF-06410293/PF-06410293	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293	Period 3: Adalimumab-EU/PF-06410293/PF-06410293	Period 3 Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	259	121	127	507
Units: subjects				
Week 52 good response	169	60	85	314
Week 52 moderate response	80	53	39	172
Week 52 no response	9	8	2	19
Week 56 good response	171	63	84	318
Week 56 moderate response	72	50	36	158
Week 56 no response	12	8	4	24
Week 66 good response	174	62	86	322
Week 66 moderate response	69	48	33	150
Week 66 no response	10	6	3	19
Week 76 good response	170	59	81	310
Week 76 moderate response	64	45	27	136
Week 76 no response	7	5	5	17
Week 78 good response	167	67	89	323
Week 78 moderate response	65	40	26	131
Week 78 no response	7	6	5	18

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects Achieving Disease Activity Score Remission (DAS <2.6): Period 1

End point title	Number of Subjects Achieving Disease Activity Score Remission (DAS <2.6): Period 1
-----------------	--

End point description:

The DAS assessment is a continuous composite measure derived using differential weighting given to each component. The components of the DAS28-4 (CRP) assessment included: tender joint count with 28 joints assessed, swollen joint count with 28 joints assessed, high-sensitivity C-reactive protein (hs-CRP) and patient's global assessment of arthritis (PGA). DAS28-4 (CRP) was calculated as  $0.56 \sqrt{\text{DAS 28 tender joint count}} + 0.28 \sqrt{\text{DAS 28 swollen joint count}} + 0.36 \ln(\text{CRP [mg/L]} + 1) + 0.014 (\text{PGA [mm]}) + 0.96$ . Higher score indicate more disease activity; DAS28-4 (CRP) <2.6 indicates remission. The analysis population included all subjects who were randomized to study treatment. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Weeks 2, 4, 6, 8, 12, 18 and 26 (pre-dose)

<b>End point values</b>	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	300		
Units: subjects				
Baseline	0	0		
Week 2	9	8		
Week 4	20	17		
Week 6	35	34		
Week 8	49	48		
Week 12	63	62		
Week 18	71	81		
Week 26 (pre-dose)	87	99		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects Achieving Disease Activity Score Remission (DAS <2.6): Period 2

End point title	Number of Subjects Achieving Disease Activity Score Remission (DAS <2.6): Period 2
-----------------	--

End point description:

The DAS assessment is a continuous composite measure derived using differential weighting given to each component. The components of the DAS28-4 (CRP) assessment included: tender joint count with 28 joints assessed, swollen joint count with 28 joints assessed, high-sensitivity C-reactive protein (hs-CRP) and patient's global assessment of arthritis (PGA). DAS28-4 (CRP) was calculated as  $0.56 \sqrt{\text{DAS 28 tender joint count}} + 0.28 \sqrt{\text{DAS 28 swollen joint count}} + 0.36 \ln(\text{CRP [mg/L]} + 1) + 0.014 (\text{PGA [mm]}) + 0.96$ . Higher score indicate more disease activity; DAS28-4 (CRP) <2.6 indicates remission. The analysis population included all subjects who completed the Period 2 randomization call. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 26, 30, 36, 44 and 52 (pre-dose)

<b>End point values</b>	Period 2: PF-06410293/PF-06410293	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	283	135	134	
Units: subjects				
Week 26	86	41	58	
Week 30	96	42	51	
Week 36	106	41	54	
Week 44	109	44	51	
Week 52 (pre-dose)	107	40	59	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects Achieving Disease Activity Score Remission (DAS <2.6): Period 3

End point title	Number of Subjects Achieving Disease Activity Score Remission (DAS <2.6): Period 3
-----------------	--

End point description:

The DAS assessment is a continuous composite measure derived using differential weighting given to each component. The components of the DAS28-4 (CRP) assessment included: tender joint count with 28 joints assessed, swollen joint count with 28 joints assessed, high-sensitivity C-reactive protein (hs-CRP) and patient's global assessment of arthritis (PGA). DAS28-4 (CRP) was calculated as  $0.56 \sqrt{\text{DAS 28 tender joint count}} + 0.28 \sqrt{\text{DAS 28 swollen joint count}} + 0.36 \ln(\text{CRP [mg/L]} + 1) + 0.014 (\text{PGA [mm]}) + 0.96$ . Higher score indicate more disease activity; DAS28-4 (CRP) <2.6 indicates remission. The analysis population included all subjects enrolled in Period 3. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 52, 56, 66, 76 and 78

End point values	Period 3: PF-06410293/PF-06410293/PF-06410293	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293	Period 3: Adalimumab-EU/PF-06410293/PF-06410293	Period 3 Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	259	121	127	507
Units: subjects				
Week 52	107	39	59	205
Week 56	111	46	57	214
Week 66	108	52	61	221
Week 76	122	45	60	227
Week 78	130	51	68	249

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects Achieving American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) ResponsePeriod 1

End point title	Number of Subjects Achieving American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) ResponsePeriod 1
-----------------	---

End point description:

Subjects were considered to be in ACR/EULAR remission when either of the following criteria was met: scores on the tender joint count, swollen joint count, hs-CRP (mg/dL) and PGA (0-10 cm scale) were all  $\leq 1$ ; or the score on the simplified disease activity index (SDAI) was  $\leq 3.3$ . SDAI score was the sum of tender joint count (28), swollen joint count (28), PGA (0-10 cm scale), physician's global assessment of arthritis (PGAA, 0-10 cm scale) and hs-CRP (mg/dL). The analysis population included all subjects who were randomized to study treatment. Not all subjects had data for each visit.

End point type Secondary

End point timeframe:

Weeks 2, 4, 6, 8, 12, 18 and 26 (pre-dose)

End point values	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	300		
Units: subjects				
Week 2	2	3		
Week 4	3	5		
Week 6	14	11		
Week 8	16	21		
Week 12	24	24		
Week 18	29	44		
Week 26 (pre-dose)	38	44		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects Achieving American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Response: Period 2

End point title Number of Subjects Achieving American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Response: Period 2

End point description:

Subjects were considered to be in ACR/EULAR remission when either of the following criteria was met: scores on the tender joint count, swollen joint count, hs-CRP (mg/dL) and PGA (0-10 cm scale) were all  $\leq 1$ ; or the score on the simplified disease activity index (SDAI) was  $\leq 3.3$ . SDAI score was the sum of tender joint count (28), swollen joint count (28), PGA (0-10 cm scale), physician's global assessment of arthritis (PGAA, 0-10 cm scale) and hs-CRP (mg/dL). The analysis population included all subjects who completed the Period 2 randomization call. Not all subjects had data for each visit.

End point type Secondary

End point timeframe:

Weeks 26, 30, 36, 44 and 52 (pre-dose)

<b>End point values</b>	Period 2: PF-06410293/PF-06410293	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	283	135	134	
Units: subjects				
Week 26	38	26	19	
Week 30	50	26	27	
Week 36	49	21	27	
Week 44	56	29	34	
Week 52 (pre-dose)	53	28	35	

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects Achieving American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Response: Period 3

End point title	Number of Subjects Achieving American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) Response: Period 3
-----------------	---

End point description:

Subjects were considered to be in ACR/EULAR remission when either of the following criteria was met: scores on the tender joint count, swollen joint count, hs-CRP (mg/dL) and PGA (0-10 cm scale) were all  $\leq 1$ ; or the score on the simplified disease activity index (SDAI) was  $\leq 3.3$ . SDAI score was the sum of tender joint count (28), swollen joint count (28), PGA (0-10 cm scale), physician's global assessment of arthritis (PGAA, 0-10 cm scale) and hs-CRP (mg/dL). The analysis population included all subjects enrolled in Period 3. Not all subjects had data for each visit.

End point type	Secondary
----------------	-----------

End point timeframe:

Weeks 52, 56, 66, 76 and 78

<b>End point values</b>	Period 3: PF-06410293/PF-06410293/PF-06410293	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293	Period 3: Adalimumab-EU/PF-06410293/PF-06410293	Period 3 Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	259	121	127	507
Units: subjects				
Week 52	53	27	34	114
Week 56	63	28	30	121
Week 66	57	31	29	117
Week 76	69	27	36	132
Week 78	77	34	43	154

## Statistical analyses

No statistical analyses for this end point

### Secondary: Serum Concentration Versus Time Summary: Period 1

End point title Serum Concentration Versus Time Summary: Period 1

End point description:

The analysis population included all subjects who received study drug and provided at least 1 post-dose drug concentration measurement in Period 1. Not all subjects had data for each visit.

End point type Secondary

End point timeframe:

Pre-dose on Days 1, 15, 43, 85 and 183, and at any time during Day 8 visit

End point values	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	299		
Units: ng/mL				
arithmetic mean (standard deviation)				
Day 1 (Week 0)	104.8 (± 1125.1)	187.3 (± 1372.7)		
Day 8 (Week 1)	3756 (± 1829.8)	3488 (± 1938.2)		
Day 15 (Week 2)	3349 (± 1601.0)	3025 (± 1729.7)		
Day 43 (Week 6)	6205 (± 3525.6)	5526 (± 3249.2)		
Day 85 (Week 12)	7575 (± 4725.1)	6531 (± 4302.5)		
Day 183 (Week 26)	8244 (± 5494.6)	7190 (± 5402.6)		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Serum Concentration Versus Time Summary: Period 2

End point title Serum Concentration Versus Time Summary: Period 2

End point description:

The analysis population included all subjects who received study drug and provided at least 1 post-dose drug concentration measurement in Period 2. Not all subjects had data for each visit.

End point type Secondary

End point timeframe:

Pre-dose on Days 183, 211, 253 and 365

<b>End point values</b>	Period 2: PF-06410293/PF-06410293	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	283	135	133	
Units: ng/mL				
arithmetic mean (standard deviation)				
Day 183 (Week 26)	8346 (± 5463.5)	7058 (± 5174.1)	7557 (± 5492.8)	
Day 211 (Week 30)	8314 (± 5728.6)	6831 (± 5147.2)	7626 (± 5335.7)	
Day 253 (Week 36)	8066 (± 5297.3)	7063 (± 5234.2)	8198 (± 5627.9)	
Day 365 (Week 52)	7491 (± 4946.9)	6252 (± 5054.5)	8157 (± 5648.5)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Serum Concentration Versus Time Summary: Period 3

End point title	Serum Concentration Versus Time Summary: Period 3
End point description:	The analysis population included all subjects who received study drug and provided at least 1 post-dose drug concentration measurement in Period 3. Not all subjects had data for each visit.
End point type	Secondary
End point timeframe:	Pre-dose on Days 365, 393, 463, 547 and 575

<b>End point values</b>	Period 3: PF-06410293/PF-06410293/PF-06410293	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293	Period 3: Adalimumab-EU/PF-06410293/PF-06410293	Period 3 Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	258	120	127	505
Units: ng/mL				
arithmetic mean (standard deviation)				
Day 365 (Week 52)	7539 (± 4933.6)	6298 (± 5063.7)	8157 (± 5648.5)	7398 (± 5184.6)
Day 393 (Week 56)	7402 (± 5190.6)	6261 (± 4999.6)	8345 (± 5255.0)	7362 (± 5202.5)
Day 463 (Week 66)	7364 (± 5118.5)	6482 (± 4879.4)	8118 (± 5507.9)	7340 (± 5183.0)
Day 547 (Week 78)	6728 (± 5003.2)	6217 (± 5118.7)	7388 (± 5380.7)	6774 (± 5134.7)
Day 575 (Follow-up)	3355 (± 3239.2)	3069 (± 3393.2)	3802 (± 3781.1)	3397 (± 3419.7)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb): Period 1

End point title	Number of Subjects With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb): Period 1
-----------------	---

End point description:

Serum samples were analyzed for the presence or absence of ADA using a semi-quantitative electrochemiluminescent (ECL) assay, and ADA positive was defined as ADA titer  $\geq 1.88$ . Serum samples tested positive for ADA were further analyzed for the presence or absence of NAb using a semi-quantitative cell-based assay, and NAb positive was defined as NAb titer  $\geq 0.70$ . The analysis population included all randomized subjects who received at least 1 dose of study drug, and had at least 1 ADA measurement in Period 1, analyzed by actual treatment received.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline up to Week 26 (pre-dose)

End point values	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	298		
Units: subjects				
ADA	132	151		
NAb	41	42		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb): Period 2

End point title	Number of Subjects With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb): Period 2
-----------------	---

End point description:

Serum samples were analyzed for the presence or absence of ADA using a semi-quantitative electrochemiluminescent (ECL) assay, and ADA positive was defined as ADA titer  $\geq 1.88$ . Serum samples tested positive for ADA were further analyzed for the presence or absence of NAb using a semi-quantitative cell-based assay, and NAb positive was defined as NAb titer  $\geq 0.70$ . The analysis population included all randomized subjects who received at least 1 dose of study treatment in Period 1, and received at least 1 dose of study treatment in Period 2, and had at least 1 ADA measurement in Period 2, analyzed by actual treatment received.

End point type	Secondary
End point timeframe:	
Week 26 dosing up to Week 52 (pre-dose)	

End point values	Period 2: PF-06410293/PF-06410293	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	283	134	133	
Units: subjects				
ADA	134	73	61	
NAb	46	18	16	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb): Period 3

End point title	Number of Subjects With Positive Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb): Period 3
-----------------	---

End point description:

Serum samples were analyzed for the presence or absence of ADA using a semi-quantitative electrochemiluminescent (ECL) assay, and ADA positive was defined as ADA titer  $\geq 1.88$ . Serum samples tested positive for ADA were further analyzed for the presence or absence of NAb using a semi-quantitative cell-based assay, and NAb positive was defined as NAb titer  $\geq 0.70$ . The analysis population included all subjects enrolled and treated in Period 3 who had at least 1 ADA measurement in Period 3.

End point type	Secondary
End point timeframe:	
Week 52 dosing up to follow-up visit (Week 92)	

End point values	Period 3: PF-06410293/PF-06410293/PF-06410293	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293	Period 3: Adalimumab-EU/PF-06410293/PF-06410293	Period 3 Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	256	120	126	502
Units: subjects				
ADA	119	65	59	243
NAb	54	30	21	105

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 1

End point title	Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 1
-----------------	--

End point description:

An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs for Period 1 were events between first dose of study drug in Period 1 and up to Week 26 pre-dose assessments that were absent before treatment or that worsened relative to pre-treatment state. Treatment-related TEAE was any untoward medical occurrence attributed to study drug. AEs included both serious and non-serious AEs. The analysis population included all randomized subjects who received at least 1 dose of study treatment, analyzed by actual treatment received.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1) up to Week 26 (pre-dose)

End point values	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	299		
Units: subjects				
All-causality TEAE	143	143		
All-causality SAE	12	13		
Treatment-related TEAE	55	69		
Treatment-related SAE	5	4		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 2

End point title	Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 2
-----------------	--

End point description:

An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs for Period 2 were events between first dose of study drug in Period 2 and up to Week 52 pre-dose assessments that were absent before treatment or that worsened relative to prior state. Treatment-related TEAE was any untoward medical occurrence attributed to study drug. AEs included both serious and non-serious AEs. The analysis population included all randomized subjects who received at least 1 dose of study treatment in Period 1, and received at least 1 dose of study

treatment in Period 2, analyzed by actual treatment received.

End point type	Secondary
End point timeframe:	
Week 26 dosing up to Week 52 (pre-dose)	

End point values	Period 2: PF-06410293/PF-06410293	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	283	135	133	
Units: subjects				
All-causality TEAE	123	60	51	
All-causality SAE	4	6	3	
Treatment-related TEAE	32	22	18	
Treatment-related SAE	2	2	0	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 3

End point title	Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Treatment Related TEAEs: Period 3
-----------------	--

End point description:

An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs for Period 3 were events between first dose of study drug in Period 3 and up to Week 92 visit that were absent before treatment or that worsened relative to prior state. Treatment-related TEAE was any untoward medical occurrence attributed to study drug. AEs included both serious and non-serious AEs. The analysis population included all subjects enrolled and treated in Period 3.

End point type	Secondary
End point timeframe:	
Week 52 dosing up to follow-up visit (Week 92)	

End point values	Period 3: PF-06410293/PF-06410293/PF-06410293	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293	Period 3: Adalimumab-EU/PF-06410293/PF-06410293	Period 3 Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	258	120	127	505
Units: subjects				
All-causality TEAE	110	61	47	218

All-causality SAE	9	9	3	21
Treatment-related TEAE	27	13	17	57
Treatment-related SAE	0	3	0	3

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Laboratory Abnormalities: Period 1

End point title	Number of Subjects With Laboratory Abnormalities: Period 1
-----------------	--

End point description:

Laboratory evaluation included hematology, clinical chemistry, and urinalysis. Each parameter was evaluated against commonly used and widely accepted criteria. Number of subjects with any laboratory abnormality during Period 1 (without regard to baseline abnormality) is presented. The analysis population included all randomized subjects who received at least 1 dose of study treatment and had laboratory test in Period 1, analyzed by actual treatment received.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1) up to Week 26 (pre-dose)

End point values	Period 1: PF-06410293	Period 1: Adalimumab-EU		
Subject group type	Subject analysis set	Subject analysis set		
Number of subjects analysed	297	298		
Units: subjects	181	180		

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Laboratory Abnormalities: Period 2

End point title	Number of Subjects With Laboratory Abnormalities: Period 2
-----------------	--

End point description:

Laboratory evaluation included hematology, clinical chemistry, and urinalysis. Each parameter was evaluated against commonly used and widely accepted criteria. Number of subjects with any laboratory abnormality during Period 2 (without regard to baseline abnormality) is presented. The analysis population included all randomized subjects who received at least 1 dose of study treatment in Period 1, and received at least 1 dose of study treatment in Period 2, and had laboratory test in Period 2, analyzed by actual treatment received.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 26 dosing up to Week 52 (pre-dose)

<b>End point values</b>	Period 2: PF-06410293/PF-06410293	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	283	134	133	
Units: subjects	171	85	73	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Laboratory Abnormalities: Period 3

End point title	Number of Subjects With Laboratory Abnormalities: Period 3
End point description:	Laboratory evaluation included hematology, clinical chemistry, and urinalysis. Each parameter was evaluated against commonly used and widely accepted criteria. Number of subjects with any laboratory abnormality during Period 3 (without regard to baseline abnormality) is presented. The analysis population included all subjects enrolled and treated in Period 3 who had laboratory test in Period 3.
End point type	Secondary
End point timeframe:	Week 52 dosing up to follow-up visit (Week 92)

<b>End point values</b>	Period 3: PF-06410293/PF-06410293/PF-06410293	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293	Period 3: Adalimumab-EU/PF-06410293/PF-06410293	Period 3 Total
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	256	120	126	502
Units: subjects	176	77	77	330

### Statistical analyses

No statistical analyses for this end point

### Other pre-specified: Delivery System Success Rate (DSSR) in Sub-study

End point title	Delivery System Success Rate (DSSR) in Sub-study
End point description:	A sub-study was conducted to determine whether subjects or their non-healthcare professional caregivers could safely and effectively administer PF-06410293 with the sponsor's prefilled pen (PFP) device. DSSR refers to the percentage of subjects who achieved delivery success. The analysis population included all subjects in the sub-study. Not all subjects had data for each visit.
End point type	Other pre-specified
End point timeframe:	Week 56 to Week 66

<b>End point values</b>	Sub-study: PF-06410293 PFP			
Subject group type	Subject analysis set			
Number of subjects analysed	50			
Units: percentage of subjects				
number (not applicable)				
Week 56	100.0			
Week 58	100.0			
Week 60	100.0			
Week 62	100.0			
Week 64	100.0			
Week 66	100.0			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From the first dose of study drug to Week 92

Adverse event reporting additional description:

The same event may appear as both an AE and a SAE. However, what is presented are distinct events. Medical Dictionary for Regulatory Affairs (MedDRA) Version 20.0 was used for Periods 1 and 2; and Version 20.1 was used for Period 3.

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20.0; 20.1
--------------------	------------

### Reporting groups

Reporting group title	Period 1: PF-06410293
-----------------------	-----------------------

Reporting group description:

This reporting group refers to the subjects who were randomized to the PF-06410293 group in Period 1, where PF-06410293 40 mg was administered every other week by subcutaneous injection.

Reporting group title	Period 2: PF-06410293/PF-06410293
-----------------------	-----------------------------------

Reporting group description:

This reporting group refers to the subjects who were randomized to the PF-06410293 group in Period 1 and continued to receive PF-06410293 in Period 2. PF-06410293 40 mg was administered every other week by subcutaneous injection in both periods.

Reporting group title	Period 1: Adalimumab-EU
-----------------------	-------------------------

Reporting group description:

This reporting group refers to the subjects who were randomized to the adalimumab-EU group in Period 1, where adalimumab-EU 40 mg was administered every other week by subcutaneous injection.

Reporting group title	Period 2: Adalimumab-EU/Adalimumab-EU
-----------------------	---------------------------------------

Reporting group description:

This reporting group refers to the subjects who were randomized to the adalimumab-EU group in Period 1 and remained in the adalimumab-EU group in Period 2. Adalimumab-EU 40 mg was administered every other week by subcutaneous injection in both periods.

Reporting group title	Period 2: Adalimumab-EU/PF-06410293
-----------------------	-------------------------------------

Reporting group description:

This reporting group refers to the subjects who were randomized to the adalimumab-EU group in Period 1 and switched to PF-06410293 in Period 2. Study drug 40 mg was administered every other week by subcutaneous injection in both periods.

Reporting group title	Period 3: PF-06410293/PF-06410293/PF-06410293
-----------------------	---

Reporting group description:

This reporting group refers to the subjects who were randomized to the PF-06410293 group in Period 1 and continued to receive PF-06410293 in Period 2 and Period 3. PF-06410293 40 mg was administered every other week by subcutaneous injection in all 3 periods.

Reporting group title	Period 3: Adalimumab-EU/Adalimumab-EU/PF-06410293
-----------------------	---

Reporting group description:

This reporting group refers to the subjects who were randomized to the adalimumab-EU group in Period 1, remained in the adalimumab-EU group in Period 2 and received PF-06410293 in Period 3. Study drug 40 mg was administered every other week by subcutaneous injection in all 3 periods.

Reporting group title	Period 3: Adalimumab-EU/PF-06410293/PF-06410293
-----------------------	---

Reporting group description:

This reporting group refers to the subjects who were randomized to the adalimumab-EU group in Period 1 and switched to PF-06410293 from Period 2 and continued on PF-06410293 in Period 3. Study drug 40 mg was administered every other week by subcutaneous injection in all 3 periods.

<b>Serious adverse events</b>	Period 1: PF-06410293	Period 2: PF-06410293/PF-06410293	Period 1: Adalimumab-EU
Total subjects affected by serious adverse events			
subjects affected / exposed	12 / 297 (4.04%)	4 / 283 (1.41%)	13 / 299 (4.35%)
number of deaths (all causes)	0	0	1
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma of colon			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	1 / 299 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibroadenoma of breast			
subjects affected / exposed	1 / 297 (0.34%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papillary thyroid cancer			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	1 / 299 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lymphoma			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer stage II			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometrial adenocarcinoma			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			

Hypertensive crisis			
subjects affected / exposed	1 / 297 (0.34%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venous thrombosis limb			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Shock			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 297 (0.00%)	1 / 283 (0.35%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	2 / 299 (0.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	1 / 299 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			

subjects affected / exposed	1 / 297 (0.34%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paranasal cyst			
subjects affected / exposed	0 / 297 (0.00%)	1 / 283 (0.35%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax spontaneous			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Intentional self-injury			
subjects affected / exposed	1 / 297 (0.34%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Panic attack			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	1 / 299 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			

Foot fracture			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	1 / 299 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	1 / 299 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Heat stroke			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic fracture			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	1 / 299 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	1 / 299 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Acute myocardial infarction			

subjects affected / exposed	0 / 297 (0.00%)	1 / 283 (0.35%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Microvascular coronary artery disease</b>			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Nervous system disorders</b>			
<b>Cerebrovascular accident</b>			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	1 / 299 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Seizure</b>			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	1 / 299 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Cerebrovascular disorder</b>			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Blood and lymphatic system disorders</b>			
<b>Anaemia</b>			
subjects affected / exposed	1 / 297 (0.34%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pancytopenia</b>			
subjects affected / exposed	1 / 297 (0.34%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastrointestinal disorders</b>			
<b>Abdominal pain</b>			
subjects affected / exposed	1 / 297 (0.34%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Haemorrhoids			
subjects affected / exposed	1 / 297 (0.34%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	1 / 299 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis chronic			
subjects affected / exposed	1 / 297 (0.34%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	1 / 297 (0.34%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal inflammation			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Irritable bowel syndrome			
subjects affected / exposed	0 / 297 (0.00%)	1 / 283 (0.35%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			

Toxic skin eruption			
subjects affected / exposed	1 / 297 (0.34%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Pelvi-ureteric obstruction			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	1 / 299 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureterolithiasis			
subjects affected / exposed	1 / 297 (0.34%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive nephropathy			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Toxic nodular goitre			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Rheumatoid arthritis			
subjects affected / exposed	0 / 297 (0.00%)	1 / 283 (0.35%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc degeneration			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			

subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
<b>Bronchitis</b>			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	1 / 299 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastroenteritis</b>			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	1 / 299 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Gastroenteritis viral</b>			
subjects affected / exposed	1 / 297 (0.34%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pneumocystis jirovecii pneumonia</b>			
subjects affected / exposed	1 / 297 (0.34%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pneumonia</b>			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	2 / 299 (0.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Pyelonephritis acute</b>			
subjects affected / exposed	1 / 297 (0.34%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Urosepsis</b>			
subjects affected / exposed	1 / 297 (0.34%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Bronchopulmonary aspergillosis</b>			

subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear infection			
subjects affected / exposed	0 / 297 (0.00%)	1 / 283 (0.35%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis salmonella			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonsillar abscess			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Postoperative wound infection			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			

subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	0 / 299 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	1 / 299 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 297 (0.00%)	0 / 283 (0.00%)	1 / 299 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Period 2: Adalimumab- EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF- 06410293	Period 3: PF- 06410293/PF- 06410293/PF- 06410293
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 135 (4.44%)	3 / 133 (2.26%)	9 / 258 (3.49%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma of colon			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibroadenoma of breast			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Papillary thyroid cancer			

subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Lymphoma</b>			
subjects affected / exposed	1 / 135 (0.74%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Breast cancer stage II</b>			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Endometrial adenocarcinoma</b>			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Vascular disorders</b>			
<b>Hypertensive crisis</b>			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Venous thrombosis limb</b>			
subjects affected / exposed	1 / 135 (0.74%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Deep vein thrombosis</b>			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Shock</b>			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>General disorders and administration site conditions</b>			

Chest pain			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Interstitial lung disease			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Paranasal cyst			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumothorax spontaneous			
subjects affected / exposed	0 / 135 (0.00%)	1 / 133 (0.75%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia aspiration			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Respiratory failure			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Intentional self-injury			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Panic attack			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Foot fracture			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Spinal compression fracture			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	1 / 135 (0.74%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper limb fracture			
subjects affected / exposed	0 / 135 (0.00%)	1 / 133 (0.75%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Heat stroke			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pelvic fracture			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	1 / 258 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	1 / 258 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	1 / 135 (0.74%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute myocardial infarction			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Microvascular coronary artery disease			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	1 / 258 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular disorder			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancytopenia			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis chronic			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal inflammation			
subjects affected / exposed	0 / 135 (0.00%)	1 / 133 (0.75%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Irritable bowel syndrome			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intestinal perforation			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper gastrointestinal haemorrhage			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Toxic skin eruption			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Pelvi-ureteric obstruction			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureterolithiasis			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive nephropathy			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Toxic nodular goitre			

subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	1 / 258 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Musculoskeletal and connective tissue disorders</b>			
Rheumatoid arthritis			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	1 / 258 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc degeneration			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Infections and infestations</b>			
Bronchitis			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis viral			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pneumonia			
subjects affected / exposed	1 / 135 (0.74%)	0 / 133 (0.00%)	1 / 258 (0.39%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis			
subjects affected / exposed	1 / 135 (0.74%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear infection			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis salmonella			
subjects affected / exposed	1 / 135 (0.74%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Influenza			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	1 / 258 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonsillar abscess			

subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	1 / 258 (0.39%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Postoperative wound infection</b>			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Sepsis</b>			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Tonsillitis</b>			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	2 / 258 (0.78%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Urinary tract infection</b>			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Metabolism and nutrition disorders</b>			
<b>Dehydration</b>			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hypokalaemia</b>			
subjects affected / exposed	0 / 135 (0.00%)	0 / 133 (0.00%)	0 / 258 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Serious adverse events</b>			
<b>Total subjects affected by serious adverse events</b>			
subjects affected / exposed	9 / 120 (7.50%)	3 / 127 (2.36%)	
number of deaths (all causes)	1	0	

number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma of colon			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fibroadenoma of breast			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Papillary thyroid cancer			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lymphoma			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Breast cancer stage II			
subjects affected / exposed	1 / 120 (0.83%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Endometrial adenocarcinoma			
subjects affected / exposed	1 / 120 (0.83%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Hypertensive crisis			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Venous thrombosis limb			

subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	1 / 120 (0.83%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shock			
subjects affected / exposed	1 / 120 (0.83%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypoxia			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Interstitial lung disease			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Paranasal cyst			

subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumothorax spontaneous			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia aspiration			
subjects affected / exposed	1 / 120 (0.83%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Pulmonary embolism			
subjects affected / exposed	1 / 120 (0.83%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	1 / 120 (0.83%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Psychiatric disorders			
Intentional self-injury			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Panic attack			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Foot fracture			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Spinal compression fracture			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fall			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper limb fracture			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Heat stroke			
subjects affected / exposed	1 / 120 (0.83%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic fracture			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Myocardial infarction			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Microvascular coronary artery			

disease			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Nervous system disorders</b>			
<b>Cerebrovascular accident</b>			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Seizure</b>			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cerebrovascular disorder</b>			
subjects affected / exposed	0 / 120 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Blood and lymphatic system disorders</b>			
<b>Anaemia</b>			
subjects affected / exposed	1 / 120 (0.83%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Pancytopenia</b>			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Gastrointestinal disorders</b>			
<b>Abdominal pain</b>			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Haemorrhoids</b>			

subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ileus			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancreatitis chronic			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Rectal haemorrhage			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal inflammation			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Irritable bowel syndrome			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal perforation			
subjects affected / exposed	0 / 120 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 120 (0.83%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Skin and subcutaneous tissue disorders			
Toxic skin eruption			

subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Renal and urinary disorders</b>			
Pelvi-ureteric obstruction			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ureterolithiasis			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive nephropathy			
subjects affected / exposed	1 / 120 (0.83%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Endocrine disorders</b>			
Toxic nodular goitre			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Musculoskeletal and connective tissue disorders</b>			
Rheumatoid arthritis			
subjects affected / exposed	1 / 120 (0.83%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	1 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intervertebral disc degeneration			
subjects affected / exposed	1 / 120 (0.83%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteonecrosis			
subjects affected / exposed	0 / 120 (0.00%)	1 / 127 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Infections and infestations			
Bronchitis			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis viral			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumocystis jirovecii pneumonia			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyelonephritis acute			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urosepsis			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bronchopulmonary aspergillosis			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear infection			

subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Gastroenteritis salmonella		
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Influenza		
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Peritonitis		
subjects affected / exposed	0 / 120 (0.00%)	1 / 127 (0.79%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Peritonsillar abscess		
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Postoperative wound infection		
subjects affected / exposed	1 / 120 (0.83%)	0 / 127 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Sepsis		
subjects affected / exposed	0 / 120 (0.00%)	1 / 127 (0.79%)
occurrences causally related to treatment / all	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0
Tonsillitis		
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
Urinary tract infection		

subjects affected / exposed	1 / 120 (0.83%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Metabolism and nutrition disorders</b>			
Dehydration			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	0 / 120 (0.00%)	0 / 127 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Period 1: PF-06410293	Period 2: PF-06410293/PF-06410293	Period 1: Adalimumab-EU
<b>Total subjects affected by non-serious adverse events</b>			
subjects affected / exposed	21 / 297 (7.07%)	15 / 283 (5.30%)	18 / 299 (6.02%)
<b>Musculoskeletal and connective tissue disorders</b>			
Rheumatoid arthritis			
subjects affected / exposed	5 / 297 (1.68%)	4 / 283 (1.41%)	3 / 299 (1.00%)
occurrences (all)	5	4	3
<b>Infections and infestations</b>			
Viral upper respiratory tract infection			
subjects affected / exposed	21 / 297 (7.07%)	15 / 283 (5.30%)	18 / 299 (6.02%)
occurrences (all)	22	17	18
Nasopharyngitis			
subjects affected / exposed	0 / 297 (0.00%)	1 / 283 (0.35%)	0 / 299 (0.00%)
occurrences (all)	0	1	0

<b>Non-serious adverse events</b>	Period 2: Adalimumab-EU/Adalimumab-EU	Period 2: Adalimumab-EU/PF-06410293	Period 3: PF-06410293/PF-06410293/PF-06410293
<b>Total subjects affected by non-serious adverse events</b>			
subjects affected / exposed	5 / 135 (3.70%)	6 / 133 (4.51%)	24 / 258 (9.30%)

Musculoskeletal and connective tissue disorders Rheumatoid arthritis subjects affected / exposed occurrences (all)	2 / 135 (1.48%) 2	3 / 133 (2.26%) 3	12 / 258 (4.65%) 14
Infections and infestations Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	5 / 135 (3.70%) 6	6 / 133 (4.51%) 6	1 / 258 (0.39%) 1
Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 135 (0.00%) 0	1 / 133 (0.75%) 1	13 / 258 (5.04%) 16

<b>Non-serious adverse events</b>	Period 3: Adalimumab- EU/Adalimumab- EU/PF-06410293	Period 3: Adalimumab-EU/PF- 06410293/PF- 06410293	
Total subjects affected by non-serious adverse events subjects affected / exposed	14 / 120 (11.67%)	15 / 127 (11.81%)	
Musculoskeletal and connective tissue disorders Rheumatoid arthritis subjects affected / exposed occurrences (all)	11 / 120 (9.17%) 11	5 / 127 (3.94%) 6	
Infections and infestations Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 120 (0.00%) 0	0 / 127 (0.00%) 0	
Nasopharyngitis subjects affected / exposed occurrences (all)	3 / 120 (2.50%) 3	10 / 127 (7.87%) 10	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
22 May 2014	Added urinalysis at Week 52 and fixed study day for follow up visit; Asia region was split to Japan and (South Korea + Taiwan) for randomization stratification; decreased entry methotrexate dose to 6 mg/week from 8 mg/week in geographic regions where 6 mg/week was a recommended initial dose by local guidance or standard of care; removed permission for use of any second disease modifying anti-rheumatic drug (DMARD) therapy, including sulfasalazine and/or anti-malarial drug during trial, and 4-week washout was required; Added recording of injection times after pharmacokinetic (PK) samples, and added time to 1 other injection before Week 12 primary endpoint that would not otherwise be recorded; added additional anti-drug antibody (ADA) sample at Week 6 as requested by the European Medicines Agency (EMA); changed ADA analysis plan to run all samples in both ADA assays as requested by the US Food and Drug Administration (FDA); added a return visit at Week 26 in subjects who withdrew before Week 26, as requested by the FDA; added follow-up telephone calls at Weeks 4 and 8 in subjects who withdrew before that, as requested by the EMA; added the option for an additional safety visit including laboratories at the discretion of the investigator, in case of any significant safety concerns at a phone follow-up, as requested by the EMA; updated permitted opioid drug tables to specify types of opioids allowed as background therapies versus those allowed as rescue therapies.
08 September 2014	Added safety telephone follow-up contact 16 weeks after final dose of study drug; added exclusion of subjects with prior history of severe allergic or anaphylactic reaction to a biologic drug, and clarified the washout period for prior investigational drugs to be the longer of the 2 stated options (4 weeks or 5 half-lives); pregnancy was added to treatment withdrawal criteria; added clarification and cross-references placed in protocol.
25 September 2014	Changed immunogenicity testing plan so that all immunogenicity samples were to be tested for ADA using a single, validated electrochemiluminescent (ECL) immunoassay for ADA against PF-06410293, instead of 2 assays; added another ADA sample, with a companion PK sample, in both treatment period 2 (TP2) and TP3 for monitoring of post switch immunogenicity time course; modified follow-up procedures for subjects who discontinued before Week 26 to require more on-site visits in TP1; modified wording for subject discontinuation due to lack of efficacy to allow some investigator discretion; specified requirements for immediate release narcotic; added supplemental urine pregnancy testing as requested by Canadian regulatory authorities.
15 July 2015	Added DMARDs to the DMARD Washout Periods table.
13 November 2015	Modified optional isoniazid prophylaxis for high-risk subjects to be globally available where standard of care during adalimumab (study drug) treatment; added an appendix describing additional GCP and inspection responsibilities; clarified that the subject would select the most appropriate form of birth control in consultation with the investigator or designee; corrected the End of Treatment (EOT)/Early Termination (ET) urine pregnancy test to occur on Week 78/Visit 18 and not during Visit 17 at Week 76; clarified maximal paracetamol dose for chronic dosing (comparable to maximal chronic acetaminophen dose already listed); for RA flare treatment, added 1 oral corticosteroid (7 day) course after study Week 26 and altered the maximal intra articular corticosteroid dose to 40 mg methylprednisolone (or equivalent) per injection.
16 May 2016	Added a prefilled pen (PFP) sub-study during TP3 to evaluate the success of PF-06410293 administration by PFP.

---

Notes:

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported

---

### **Online references**

<http://www.ncbi.nlm.nih.gov/pubmed/30111357>